Enhancing binding affinity of an intrinsically disordered protein by α-methylation of key amino acid residues

Valentin Bauer[1†], Boris Schmidtgall[1†], Gergő Gógl[2#], Jozica Dolenc[3], Judit Osz[2], Yves Nominé[2#], Camille Kostmann[2#], Alexandra Cousido-Siah[2#], André Mitschler[2#], Natacha Rochel[2], Gilles Travé[2#], Bruno Kieffer[2] and Vladimir Torbeev[1*]

[1] Institut de Science et d'Ingénierie Supramoléculaires (ISIS), International Center for Frontier Research in Chemistry (icFRC), University of Strasbourg, CNRS (UMR 7006), Strasbourg, France. *Correspondence should be addressed to V. T. (torbeev@unistra.fr).

[2] Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM (U964), University of Strasbourg, CNRS (UMR 7104), Illkirch, France

[3] Chemistry | Biology | Pharmacy Information Center, ETH Zurich, Zurich, Switzerland

[†] - these authors equally contributed to this work

[#] - Équipe Labellisée Ligue 2015

Abstract

Intrinsically disordered proteins (IDPs), which undergo folding upon binding to their targets, are critical players in protein interaction networks. Here we demonstrate that incorporation of non-canonical α-methylated amino acids into the unstructured activation domain of the transcriptional coactivator ACTR can stabilize helical conformations and strengthen binding interactions with the nuclear coactivator binding domain (NCBD) of CREB-binding protein (CBP). A combinatorial α-methylation scan of the ACTR sequence converged on two substitutions at positions 1055 and 1076 that increase affinity for both NCBD and the full-length 270 kDa CBP by one order of magnitude. The first X-ray structure of the modified ACTR domain bound to NCBD revealed that the key α-methylated amino acids were localized within α-helices. Biophysical studies showed that the observed changes in binding energy are the result of long-range interactions and redistribution of enthalpy and entropy. This proof-of-concept study establishes a potential strategy for selective inhibition of protein-protein interactions involving IDPs in cells.

INTRODUCTION

Intrinsically disordered proteins (IDPs) and protein domains complement the functions of well-folded proteins[1-3]. They are particularly abundant in eukaryotes, where they contribute to the higher complexity of biological organization and regulatory processes[4]. Intrinsic disorder confers distinctive molecular recognition and structural properties compared to well-folded proteins[5]. These include high affinity even if the complexes remain unstructured[6], multivalent interactions that may lead to phase separation[7,8], and promiscuity in forming complexes with structurally unrelated targets[9].

The gene transcription machinery of eukaryotes is particularly rich in IDPs[10,11] where intrinsic disorder plays a key role, providing high structural and compositional diversity in protein complexes that regulate gene expression[12-14]. More than a half of eukaryotic transcription factors are predicted to contain highly disordered regions, especially within their activation domains[15]. Thus, being able to target IDPs could represent an attractive strategy to interfere with biological processes at the level of gene transcription[16]. However, a lack of well-structured binding pockets makes it challenging to identify molecules, either by design or high-throughput screening, that bind IDPs specifically and with high affinity[17].

In general, folding of IDPs upon complex formation leads to a large loss of conformational entropy[18]. Introduction of conformational constraints that minimize such losses is one approach to enhance overall affinity. For example, side-chains in peptide fragments of the IDP that correspond to the most important site at the protein-protein interaction (PPI) interface can be covalently tethered. The successful development of stapled peptides as inhibitors of PPIs is illustrative of this strategy[19]. Nevertheless, such methods are best suited to protein complexes where binding energy is localized over a few proximal residues and not dispersed over several distant regions of the protein surface.

As an alternative, we are exploring backbone conformational constraints as a means to enhance binding affinity of protein-protein interactions involving IDPs (Fig. 1). We chose a complex formed by domains from two transcriptional coactivators, CBP (CREB-binding protein)[20] and ACTR (activator for thyroid hormone and retinoid receptors; also called SRC3 - steroid receptor coactivator 3 from p160 family),[21] to implement this strategy. Both CBP (and its paralog p300) and ACTR function as cellular integrators of various signalling pathways that transduce these signals into fine-tuned transcriptional outputs[20-22]. In its isolated state, the nuclear coactivator binding domain (NCBD) of CBP has the properties of a molten globule with residual helical structure,[23] whereas the activation domain 1 (AD1) of ACTR (Fig. 1b) is highly disordered[24]. Together, they undergo coupled binding and folding to form a complex that is predominantly α-helical[25].

One efficient way to stabilize helical conformations involves introduction of non-canonical α-methylated amino acids (Fig. 1c)[26]. The additional methyl group increases steric bulk insignificantly, while side-chains important for protein-protein interactions are left unmodified. Here, to illustrate the potential of this approach, we assembled a combinatorial library of α-methylated AD1-ACTR variants and performed biophysical studies to characterize their binding to NCBD. The NCBD and AD1-ACTR domains are both ~50 residues long and can be synthesized chemically[27]. Hence, single or multiple α-methylated amino acids can be introduced at any site in their sequences. This effort led to the discovery of a set of variants with enhanced affinity for the isolated NCBD as well as for the full length, 270 kDa CBP. The

key advantage of the approach developed herein is that modified (α-methylated) protein domains form nearly native protein-protein interaction interfaces, which will retain unique specificity for their target. Moreover, α-methylated peptides are protease-resistant,[28] a strong advantage for *in vivo* applications.

RESULTS

Combinatorial library of α-methylated variants of AD1-ACTR. Prior to our study, no crystal structure of the AD1-ACTR/NCBD complex was available. However, the structure of an AD1-ACTR/NCBD complex in solution had been determined by NMR and showed that the two proteins each contribute three α-helices to a tight hydrophobic interface.[25] The seventeen sites in the [1040-1086] fragment of AD1-ACTR that we chose for α-methylation are depicted in Fig. 1c, and the corresponding sequences are listed in Supplementary Table 1. The substituted residues are located in α-helical segments, in loop regions, at the buried AD1-ACTR/NCBD protein interface, and on the solvent-accessible surface of the protein complex. Single and multiple substitutions were made, with up to six α-methylated amino acids introduced simultaneously. In total, we prepared 17 single, 22 double, 2 triple, 4 tetra, 1 penta and 1 hexa α-methylated analogues. In addition, we have synthesized two variants containing canonical amino acids with different helical propensities [S1043M;D1050E;T1054Q] and [A1047G] previously reported to have distinct binding properties to NCBD[24]. To assemble the 50 variants of AD1-ACTR (Supplementary Tables 1 and 2), we used combinatorial native chemical ligation of N-terminal and C-terminal peptide precursor segments as described previously[27]. In a few cases, the entire polypeptide chain was assembled by microwave-assisted solid-phase peptide synthesis (see Supplementary Materials and Methods).

α-Methylation modifies the affinity of AD1-ACTR binding to NCBD. Isothermal titration calorimetry was used to characterize the formation of complexes between α-methylated variants of AD1-ACTR and NCBD (the [2066–2112]-fragment of CBP) to obtain Gibbs free energy (ΔG) as well as the enthalpy (ΔH) and entropy (-TΔS) of binding. The results of measurements at T = 304 K are summarized in Fig. 2 and Supplementary Table 3 and indicate that the effect of α-methylation on complex formation is position-dependent (binding diagrams are depicted in Supplementary Fig. 1).

Despite the helix-inducing tendencies of α-methylated amino acids, α-methylation caused a decrease in complex stability in most cases. The greatest destabilization (ΔΔG ~ 1.5-2.0 kcal/mol) occurred for variants when Leu1071 was replaced by its α-methylated analogue. Other substitutions that resulted in significant destabilization were meLeu1056, meLeu1064, meLeu1049 and meAsp1050. The decrease in stability may be due to unfavorable steric interactions or incorrect folding. α-Methylation increases local steric interactions between backbone and side chain and can also alter side-chain rotamer conformations[29]. Furthermore, the energy difference between right- and left-handed helical conformations for α,α-disubstituted residues is lower than for canonical α-amino acids[29]. For example, the most destabilizing meLeu1071 is located next to achiral Gly1072, which may allow meLeu1071 to induce a non-native left-handed helical conformation and thus lead to incorrect folding.

However, we identified a few sites where α-methylation enhanced binding. Complexes with the highest stability were obtained when meLeu1055 was introduced (ΔΔG = -0.61

kcal/mol), whereas the 1047meAla-containing variant exhibited slightly increased binding affinity for NCBD ($\Delta\Delta G$ = -0.21 kcal/mol). Given its exceptionally favorable effect on overall affinity (ΔG) of complexation to NCBD, residue 1055 can be regarded as a 'hot-spot'[30] in the α-methylation scan experiment.

The binding of wild-type AD1-ACTR to NCBD is enthalpy-driven. Formation of favorable inter-residue contacts in the resulting complex presumably compensates for the loss of entropy due to coupled folding.[31] Incorporation of α-methylated amino acids resulted in changes in the enthalpic (ΔH) and entropic ($-T\Delta S$) contributions to binding depending on the position and number of substituted residues (Fig. 2b). Thus, the AD1-ACTR analogue with 1055meLeu at the 'hot spot' site in the N-terminal helix exhibits an anomalously favorable ΔH, offset by a more unfavorable $-T\Delta S$ than seen for the wild type protein domain. Similarly, higher enthalpy-entropy compensation was observed for variants with substitutions in the C-terminal helix (*e.g.,* 1076meLeu, 1077meVal, 1080meAla, 1083meAla). In contrast, compensation with the opposite sign (enthalpy became less favorable while entropy more favorable) was observed for the highly destabilized complexes containing 1071meLeu or 1056meLeu.

Increasing the number of α-methylated residues further reinforced the observed enthalpy-entropy compensation. The elevated ΔH and $-T\Delta S$ contributions are consistent with the formation of more stable electrostatic or hydrogen bonding interactions, leading to gains in ΔH that are counter-balanced by losses in conformational degrees of freedom ($-T\Delta S$) resulting from reduced accessible values of the Ramachandran (φ,ψ)-dihedral angles. The most elevated values of $-T\Delta\Delta S$ (7.3-8.6 kcal/mol) relative to wild type are seen for the tetra-, penta- and hexa-substituted variants, which would correspond to folding of approximately 5 to 6 additional residues assuming the theoretically estimated value for entropy changes upon folding of 1.4 kcal/mol per residue[33].

The large set of variants in the library containing two α-methylations enabled assessment of coupling energies (cross-talk) between the modified sites in the sequence. Standard "double-mutant cycle" analyses were performed according to the relationship $\Delta\Delta\Delta G = \Delta\Delta G_{variant-X} + \Delta\Delta G_{variant-Y} - \Delta\Delta G_{double-XY}$, where $\Delta\Delta G_{variant}$ is the variation in Gibbs free energy for a singly modified ACTR variant and $\Delta\Delta G_{double-XY}$ is the variation in Gibbs free energy for the doubly α-methylated protein[34]. The Gibbs free energy for most of the analogues (nearly 70%) containing two modifications displays positive cooperativity ($\Delta\Delta\Delta G > 0$ in the 0.25-1.0 kcal/mol range); for several variants it is nearly 0; and only one, [1047Aib;1072Aib], shows significant negative cooperativity ($\Delta\Delta\Delta G$ = -0.82 kcal/mol) (Supplementary Fig. 2). These findings indicate that multiple α-methylations are generally more favorable for protein complex stability than the theoretical combination of the corresponding single modifications even if they are destabilizing when introduced individually. These results support the notion that the protein interfaces of IDP complexes, and the AD1-ACTR/NCBD complex in particular, are non-optimal or "frustrated"[35].

An AD1-ACTR variant with two α-methylations ([1055meLeu; 1076meLeu]) was found to be the best NCBD binder in the entire library (variant 34 in Supplementary Table 1). According to ITC, it exhibits approximately 5-fold stronger affinity (K_D = 0.042 μM) at 304 K than WT AD1 (K_D = 0.206 μM). The 1076meLeu substitution alone had nearly no effect on the binding of AD1-ACTR to NCBD but when combined with 1055meLeu it contributed to enhanced affinity. Note that insertion of a larger number of α-methylated residues does not

necessarily improve binding. Indeed, several variants containing four, five and six α-methylated amino acids bound NCBD with lower affinity than [1055meLeu;1076meLeu]AD1-ACTR. The more favorable enthalpic contributions provided by these substitutions were 'overridden' in most cases by losses in entropy.

Shorter peptide fragments corresponding to the most structured N-terminal portion of AD1-ACTR, including a peptide containing meLeu at the 1055 'hot spot', did not show appreciable binding to NCBD. For efficient binding, the full-length AD1-ACTR sequence is apparently essential.

α-Methylation induces helical structure in the disordered ACTR activation domain. Circular dichroism of the isolated AD1-ACTR domain indicates a highly disordered protein that is mostly random coil with only a small percentage of α-helical structure. Upon α-methylation, helical content increased for all members of the library judging from the ratio of ellipticities for α-helix versus random coil, $\theta_{222}/\theta_{199}$ (Supplementary Figs. 3, 4a and Table 5). Moreover, α-methylation of the 'hot spot' residue 1055 had a greater effect on α-helical content than modification of any other residue. Thus, the $\theta_{222}/\theta_{199}$ value for [1055meLeu]AD1-ACTR is significantly higher than for wild type (0.44 versus 0.23) and progressively increases when other α-methylated residues are added. For comparison, a previously reported triple mutant [S1043M;D1050E;T1054Q] that was engineered to have high α-helicity by incorporating residues with high helical propensities[24] has a lower α-helical content ($\theta_{222}/\theta_{199} = 0.33$, measured in our lab) than [1055meLeu]AD1-ACTR, showing that α-methylated amino acids are superior to standard amino acids at inducing helical structure. This is also reflected in the triple mutant's lower affinity for NCBD (K_D for [S1043M;D1050E;T1054Q] variant is 0.188 μM versus 0.204 μM for WT and 0.042 μM for [1055meLeu;1076meLeu]AD1-ACTR as measured by ITC at 304 K).

NMR analysis provided residue-specific insights into the structural changes induced by α-methylation of residues 1055 and 1076. ^{1}H-^{13}C HSQC spectra were recorded for the wild type domain and two variants, [1055meLeu]AD1-ACTR and [1055meLeu,1076meLeu]AD1-ACTR (Supplementary Fig. 6). Assignment of Hα, Cα and Cβ resonances was achieved using a combination of ^{1}H-TOCSY, ^{1}H-NOESY, ^{1}H-^{13}C HSQC and HMBC experiments (Supplementary Figs. 7-8 and Tables 7-10). The backbone chemical shifts in the two variants were compared with random coil values[36]. In both cases, positive deviations in ^{13}Cα chemical shifts indicate the presence of helical conformation in the vicinity of meLeu1055 and meLeu1076 (Fig. 3a). Moreover, local enhancement of helicity at position 1055 propagates towards the N-terminus, resulting in stabilization of the helical structure via long-range effects.

Although longitudinal relaxation rates (R_1) were not affected by α-methylation (Supplementary Fig. 9 and Table 10), elevated values for transverse relaxation rates (R_2) were observed, particularly for residues near 1055meLeu (Fig. 3b, Supplementary Table 11). These results likely reflect the contribution of conformational exchange (R_{ex}) between locally folded and unfolded states, usually a very fast dynamical process that is presumably slowed down to the chemical shift time scale (μs-ms).

X-ray structure of the [1055meLeu;1076meLeu]AD1-ACTR complex with NCBD. In an attempt to obtain high-resolution structural information, we tethered NCBD to a crystallization-prone mutant of the maltose binding protein (MBP)[37]. While the complex of

wild-type AD1-ACTR with MBP-fused NCBD did not yield crystals, we succeeded in solving an X-ray structure of the analogous complex with the best binder, [1055meLeu;1076meLeu]AD1-ACTR (Fig. 4a, Supplementary Figs. 11-15 and Table 12). The X-ray diffraction data were collected at 2.2 Å resolution and the structure was solved by molecular replacement using a high resolution MBP crystal structure and the previously reported NMR structure of AD1-ACTR[25].

A comparison of the crystallized complex with the two NMR structures of activation domain of ACTR and NCBD, as well as other structures of NCBD is provided in Supplementary Fig. 12. The overall arrangement of the three AD1-ACTR helices in the crystal structure is most similar to the NMR structure with PDB ID: 1KBH. However, the interaction interface with NCBD in the crystal is less tight than in the NMR structure, with the overall buried surface area (BSA) decreasing to 1066 Å from 1655 Å for 1KBH structure (Supplementary Fig. 14). The most prominent difference is seen in the C-terminal helix, which no longer forms a tight interface with NCBD in the X-ray structure. Analysis of crystal packing did not reveal any interactions with symmetry related molecules (Supplementary Fig. 15), suggesting that this is not a crystal packing artifact. In [meLeu1055;meLeu1076]AD1-ACTR, both meLeu residues adopt canonical α-helical backbone conformations with (φ,ψ)-angles of -58.2º, -65.3º for meLeu1055 and -39.9º, -57.0º for meLeu1076, respectively (Fig. 4 a). This result further supports our hypothesis that α-methylation can be used to stabilize α-helical structures in IDPs.

A comparison with another available NMR structure of the complex (PDB ID: 6ES7)[39], shows much larger deviations including a completely different orientation of the C-terminal helix of AD1-ACTR. The same is true for the NMR structure of the complex of NCBD with a homologous activation domain from SRC-1 isoform of p160 (PDB ID: 2C52)[40] in which only the NCBD chain and N-terminal helix of SRC-1 can be reasonably superimposed, whereas the remaining part of SRC-1 adopts a completely different conformation.

α-Methylation attenuates the conformational dynamics of AD1-ACTR/NCBD complex. Explicit-solvent all-atom molecular dynamics (MD) simulations were performed for 200 ns for the wild-type AD1-ACTR/NCBD complex as well as for two complexes with the α-methylated analogues [1055meLeu]AD1-ACTR and [1055meLeu,1076meLeu]AD1-ACTR. As can be seen from the reduced RMSF (root-mean-square fluctuations) of backbone atom positions in the complexes with the variants compared to wild type (Fig. 4b), α-methylation at positions 1055 and 1076 causes a substantial decrease in the amplitudes of motion. Moreover, the overall shape of the α-methylated complexes was more compact as judged by their radii of gyration (Supplementary Fig. 16b). In addition, the (φ,ψ)-backbone conformations were clearly constrained by α-methylation for the α-methylated amino acids as well as for nearby residues (Fig. 4c and Supplementary Fig. 16d).

The higher stability of the α-methylated complexes can also be inferred from the overall higher occurrence of hydrogen bonds in the corresponding complexes than in the wild type complex (Supplementary Table 13). A salt bridge analysis showed different patterns of populated salt bridges (Supplementary Table 14). Given the non-optimal ("frustrated") interface between AD1-ACTR and NCBD[35], deviations of the average structure of the α-methylated complexes from the corresponding structure of the wild-type complex would be

expected. Different chemical shifts in the ^{1}H-^{13}C HSQC spectra of the [1055meLeu;1076meLeu] variant complexed with NCBD and the corresponding wild-type complex support this possibility, especially for the methyl resonances of aliphatic side chains indicating non identical hydrophobic protein-protein interfaces (Supplementary Fig. 10).

[1055meLeu;1076meLeu]AD1-ACTR is a superior binder both to NCBD and to full length CBP. CBP (like its paralog p300) is a large (270 kDa) multi-domain protein containing folded and unstructured domains, including NCBD[20]. To test molecular recognition of methylated AD1-ACTR variants by CBP in comparison to isolated NCBD and whether these modified sequences bind CBP more potently than wild-type we performed surface plasmon resonance (SPR) experiments (Fig. 5). The C-termini of wild-type AD1-ACTR and [1055meLeu;1076meLeu]AD1-ACTR were conjugated to biotin via a polyethyleneglycol spacer, and the proteins were immobilized on the chip via biotin - streptavidin approach. Singly α-methylated variants [1055meLeu]AD1-ACTR, [1076meLeu]AD1-ACTR and a weak binder [1064meLeu;1071meLeu]AD1-ACTR were prepared in the same way to use as additional experimental points and a negative control, respectively.

The kinetics and thermodynamics of binding to NCBD were measured at five different temperatures (from 20 to 31 °C). The [1055meLeu;1076meLeu]AD1-ACTR analogue proved to be the best binder at all temperatures, with a binding affinity (K_D) strengthened by 11-14 fold in comparison to wild-type (the tightest binding at ~15 nM was observed at 20 °C, see Supplementary Table 16). This effect originates in the dissociation kinetics that is affected most strongly (k_{off} was reduced by an order of magnitude), whereas the association kinetics were affected to a lesser extent and is only slightly increased for the dimethylated variant (Supplementary Table 15). Finally, the higher binding affinity of [1055meLeu;1076meLeu]AD1-ACTR was confirmed for full-length CBP (apparent K_D improved from ~1.2 μM to ~60 nM at 10 °C) (Supplementary Fig. 20), suggesting that conformational editing of an intrinsically disordered domain by α-methylation can be used to derive a selective and high affinity binder with the ability to target a multi-domain binding partner.

DISCUSSION

Protein engineering has been successfully applied to elucidate the mechanistic details of folding and complex formation of many proteins[41,42]. In a typical study, amino acid residues are substituted with analogues that contain smaller side-chains, often alanine (Ala) in Ala-scanning mutagenesis[30]. The resulting alteration of interactions, when performed systematically with single-residue resolution, provides insight into the importance of each residue for the stability of the folded protein or protein complex. In addition, Φ-values, defined as the ratio of the free energy destabilization of transition state versus ground state upon mutation, can be derived to evaluate the structural roles of specific residues in folding mechanisms[43]. Double mutant cycles can also be used to determine the effects of long range inter-residue cooperativity[34]. This set of tools has enabled comprehensive analysis of many protein systems.

In this work, we have developed a different strategy to study folding and complex formation that is particularly useful for IDPs. Instead of altering interactions by replacing large residues by smaller ones, which generally causes destabilization, we reinforced inter-residue contacts by conformationally constraining backbone φ/ψ-dihedral angles in a residue-specific manner. α-Helical conformations, which are very abundant in IDP complexes, can be enhanced locally by strategic incorporation of α-methyl groups[26,29]. A significant advantage of this approach is the preservation of the native amino acid side chains that mediate inter-residue contacts.

Our results with the intrinsically disordered transcription coactivator ACTR domain validate the potential of this strategy. In addition to showing that α-methylation can modulate the free energy landscape of coupled binding and folding, we discovered several α-methylated variants of AD1-ACTR with enhanced affinity for NCBD, its natural binding partner. *A priori* prediction of positions for α-methylation that increase α-helical content and also improve binding affinity is not trivial, however. Stabilization does not simply correlate with amino acid secondary structure propensities, since replacing a helix-favoring Leu amino acid with its α-methylated counterpart at two different sites in the sequence (*i.e.,* 1055 and 1071 both in helical segments) gave totally opposite effects. Choosing appropriate methylation sites based on structural data is also challenging because IDP complexes often possess a certain degree of "fuzziness"[44] and can adapt to small perturbations, such as introduction of a few α-methyl groups, with hard-to-predict structural and dynamic consequences. Our combinatorial library approach was therefore essential for effectively exploring position- and context-dependence as well as long-range interactions between distant residues. Overall, approximately 30% of the variants were found to bind the NCBD domain of CBP more tightly than wild-type AD1-ACTR, whereas the remaining 70% bound more weakly. Most likely, for most of the positions, including analogues with multiple substitutions, α-methylation can lead to alternative conformations of side-chains and/or steric clashes.

For the best binding variant, [1055meLeu;1076meLeu]AD1-ACTR, we succeeded in obtaining the first crystal structure of this transcriptional activator in complex with its binding partner NCBD. The X-ray data complement and extend previous structural information gleaned by NMR spectroscopy[25,39]. A comparison of crystal structure and NMR structures generally supports the notion that the N-terminal helix of AD1-ACTR is critical for complex formation[45,46] as it superimposes rather well for all structures, whereas the rest of the sequence of AD1-ACTR is rather malleable. A given AD1-ACTR conformer "caught" in the crystal resulted in high accuracy structural information, which can be used for designing small molecules that can specifically bind and allosterically modulate the interaction between NCBD and wild-type AD1-ACTR. As our failure to crystallize the more dynamic wild-type complex attests, crystallizing complexes resulting from the mutual interactions of IDPs can be difficult, so targeted α-methylation could conceivably become a valuable tool for structurally characterizing the complexes formed by many other IDPs. So-called "fuzzy" complexes that exhibit substantial binding affinities and specificities despite enhanced conformational dynamics would be particularly interesting in this regard[44].

Among singly methylated AD1-ACTR variants, substitution of Leu with meLeu at position 1055 in AD1-ACTR provided the largest increase in binding affinity for NCBD. In this case, α-methylation results in a "gain-of-function". In contrast, when this residue was replaced by Ala for Φ-value analysis of the protein, a weaker binding constant was obtained, constituting a

"loss-of-function" due to substitution of a bulky isopropyl moiety with a smaller methyl group[45]. Notably, this was the only site in the protein that gave an elevated Φ-value (close to 0.8), indicating that residue 1055 adopts a near native conformation in the folding transition state[45].

Consistent with this interpretation, NMR measurements showed that α-methylation of Leu1055 leads to partial folding of the N-terminal helix in free AD1-ACTR protein resulting in faster association and slower dissociation rates with NCBD (Fig. 5a). The acceleration of binding reflects a reduction of Gibbs free energy barrier for folding: for instance, the residue 1055, which is most important for folding, is already pre-folded in free [1055meLeu]AD1-ACTR variant. Slower dissociation results from higher stability of complex and enhanced barrier for unfolding.

Thus, our results are consistent with previous data suggesting that coupled binding and folding of AD1-ACTR and NCBD occurs via an induced fit mechanism in which the two highly unstructured polypeptides undergo major conformational rearrangements to form the well-structured final protein complex[27]. The observed increased on-rate (k_{on}), in particular upon α-methylation of AD1-ACTR residue 1055, reveals that elements of conformational selection are also likely operative. Thus, the overall mechanism of complex formation may be best explained by 'extended conformational selection'[47] or 'conformational funneling'[48] models, which synergistically combine both induced fit and conformational selection mechanisms.

A particularly intriguing consequence of our work is the possibility of using α-methylated IDPs to inhibit native PPIs. Both CBP and ACTR have been implicated in various diseases (neurological, metabolic disorders and cancers), and regulating their function has been proposed as a possible means of therapeutic intervention.[49,50] Indeed, potent small molecule inhibitors have been developed for the well-structured histone acetyltransferase (HAT) domain in CBP/p300[51]. However, intrinsically disordered domains in large, complex proteins such as CBP and ACTR are often considered to be 'undruggable' by small molecules[52]. Formation of complexes between IDPs is governed by different physicochemical principles than well-folded proteins[5,18]. Delocalization of binding energy over a large surface area may be the most important difference, making it difficult for small molecules to compete with the native protein binding partners. Our results establish the feasibility of an alternative approach that is based on conformational editing of the IDP domain itself, utilizing backbone conformational constraints to enhance the native structural features and facilitate binding to the protein target. Remarkably, CBP, which contains nine interaction domains in addition to NCBD[21], senses the presence of two extra α-methyl groups in the [1055meLeu;1076meLeu]AD1-ACTR variant and binds it more tightly than wild type AD1-ACTR. We anticipate that such modified peptides may serve as useful lead compounds for development of potent inhibitors that can be used in cell culture to probe the diverse roles of CBP/p300 and ACTR in signaling and regulation pathways in gene transcription. Furthermore, the feasibility of biosynthetic incorporation of α-methylated amino acids into proteins via stop codon suppression using aminoacylated tRNA was demonstrated previously.[53] Therefore, the conformational editing of interaction domains of IDPs can in principle be performed via an expanded genetic code[54].

References:

1. van der Lee R. et al. Classification of intrinsically disordered regions and proteins. *Chem. Rev.* **114**, 6589-6631 (2014).

2. Oldfield, C. J., Dunker, A. K. Intrinsically disordered proteins and intrinsically disordered protein regions. *Annu. Rev. Biochem.* **83**, 553-584 (2014).

3. Wright, P. E., Dyson, H. J. Intrinsically disordered proteins in cellular signaling and regulation. *Nat. Rev. Mol. Cell. Biol.* **16**, 18-29 (2015).

4. Pancsa, R., Tompa, P. Structural disorder in eukatyotes. *PLoS ONE* **7**, e34687 (2012).

5. Uversky, V. N. Unusual biophysics of intrinsically disordered proteins. *Biochim. Biophys. Acta* **1834**, 932-951 (2013).

6. Borgia, A., Borgia, M. B., Bugge, K., Kissling, V. M., Heidarsson, P. O., Fernandes, C. B., Sottini, A., Soranno, A., Buholzer, K. J., Nettels, D., Kragelund, B. B., Best, R. B., Schuler, B. Extreme disorder in an ultrahigh-affinity protein complex. *Nature* **555**, 61-66 (2018).

7. Brangwynne, C. P., Tompa, P., Pappu, R. V. Polymer physics of intracellular phase transitions. *Nat. Phys.* **11**, 899-904 (2015).

8. Banani, S. F., Lee, H. O., Hyman, A. A., Rosen, M. K. Biomolecular condensates: organizers of cellular biochemistry. *Nat. Rev.* **18**, 285-298 (2017).

9. Dunker, A. K., Cortese, M. S., Romero, P., Iakoucheva, L. M., Uversky, V. N. Flexible nets. The roles of intrinsic disorder in protein interaction networks. *FEBS J.* **272**, 5129-5148 (2005).

10. Fuxreiter, M., Tompa, P., Simon, I., Uversky, V. N., Hansen, J. C., Asturias, F. J. Malleable machines take shape in eukaryotic transcriptional regulation. *Nat. Chem. Biol.* **4**, 728-737 (2008).

11. Shammas, S. L. Mechanistic roles of protein disorder within transcription. *Curr. Opin. Struct. Biol.* **42**, 155-161 (2017).

12. Martinez, E. Multi-protein complexes in eukaryotic gene transcription. *Plant Molecular Biology* **50**, 925-947 (2002).

13. Nakagawa, T., Yoneda, M., Higashi, M., Ohkuma, Y., Ito, T. Enhancer function regulated by combinations of transcription factors and cofactors. *Genes Cells* **23**, 808-821 (2018).

14. Perissi, V., Rosenfeld, M. G. Controlling nuclear receptors: the circular logic of cofactor cycles. *Nat. Rev.* **6**, 542-554 (2005).

15. Liu, J., Perumal, N. B., Oldfield, C. J., Su, E. W., Uversky, V. N., Dunker, A. K. Intrinsic disorder in transcription factors. *Biochemistry* **45**, 6873-6888 (2006).

16. Dunker, A. K., Uversky, V. N. Drugs for 'protein clouds': targeting intrinsically disordered transcription factors. *Curr. Opin. Pharmacol.* **10**, 782-788 (2010).

17. Scott, D. E., Bayly, A. R., Abell, C., Skidmore, J. Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. *Nat. Rev.* **15**, 533-550 (2016).

18. Flock, T., Weatheritt, R. J., Latysheva, N. S., Babu, M. M. Controlling entropy to tune the functions of intrinsically disordered regions. *Curr. Opin. Struct. Biol.* **26**, 62-72 (2014).

19. Walensky, L. D., Bird, G. H. Hydrocarbon-stapled peptides: principles, practice, and progress. *J. Med. Chem.* **57**, 6275-6288 (2014).

20. Vo, N., Goodman, R. H. CREB-binding protein and p300 in transcriptional regulation. *J. Biol. Chem.* **276**, 13505-13508 (2001).

21. Dyson, H. J., Wright, P. E. Role of intrinsic protein disorder in the function and interactions of the transcriptional coactivators CREB-binding protein (CBP) and p300. *J. Biol. Chem.* **291**, 6714-6722 (2016).

22. Xu, J., Wu, R.-C., O'Malley, B. W. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. *Nat. Rev.* **9**, 615-630 (2009).

23. Kjaergaard, M., Teilum, K., Poulsen, F. M. Conformational selection in the molten globule state of the nuclear coactivator binding domain of CBP. *Proc. Natl. Acad. Sci. USA* **107**, 12535-12540 (2010).

24. Iesmantavicius, V., Dogan, J., Jemth, P., Teilum, K., Kjaergaard, M. Helical propensity in an intrinsically disordered protein accelerates ligand binding. *Angew. Chem. Int. Ed.* **53**, 1548-1551 (2014).

25. Demarest, S. J., Martinez-Yamout, M., Chung, J., Chen, H., Xu, W., Dyson, H. J., Evans, R. M., Wright, P. E. Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. *Nature* **415**, 549-553 (2002).

26. Kaul, R., Balaram, P. Stereochemical control of peptide folding. *Bioorg. Med. Chem.* **7**, 105-117 (1999).

27. Schmidtgall, B., Chaloin, O., Bauer, V., Sumyk, M., Birck, C., Torbeev, V. Dissecting mechanism of coupled folding and binding of an intrinsically disordered protein by chemical synthesis of conformationally constrained analogues. *Chem. Commun.* **53**, 7369-7372 (2017).

28. Werner, H. M., Cabalteja, C. C., Horne, W. S. Peptide backbone composition and protease susceptibility: impact of modification type, position, and tandem substitution. *Chembiochem* **17**, 712-718 (2016).

29. Crisma, M., Toniolo, C. Helical screw-sense preferences of peptides based on chiral, Cα-tetrasubstituted α-amino acids. *Biopolymers* **104**, 46-64 (2014).

30. Clackson, T., Wells, J. A. A hot spot of binding energy in a hormone-receptor interface. *Science* **267**, 383-386 (1995).

31. Dobson, C. M., Šali, A., Karplus, M. Protein folding: a perspective from theory and experiment. *Angew. Chem. Int. Ed.* **37**, 868-893 (1998).

32. Clodera, J. D., Mobley, D. L. Entropy-enthalpy compensation: role and ramifications in biomolecular ligand recognition and design. *Annu. Rev. Biophys.* **42**, 121-142 (2013).

33. Baxa, M. C., Haddadian, E. J., Jumper, J. M., Freed, K. F., Sosnick, T. R. Loss of conformational entropy in protein folding calculated using realistic ensembles and its implications for NMR-based calculations. *Proc. Natl. Acad. Sci. USA* **111**, 15396-15401 (2014).

34. Horovitz, A., Fersht, A. R. Co-operative interactions during protein folding. *J. Mol. Biol.* **224**, 733-740 (1992).

35. Jemth, P., Mu, X., Engström, Å., Dogan, J. A frustrated binding interface for intrinsically disordered proteins. *J. Biol. Chem.* **289**, 5528-5533 (2014).

36. Tamiola, K., Acar, B., Mulder, F. A. Sequence-specific random coil chemical shifts of intrinsically disordered proteins. *J. Am. Chem. Soc.* **132**, 18000-18003 (2010).

37. Zanier, K., Charbonnier, S., Sidi, A. O., McEwen, A. G., Ferrario, M. G., Poussin-Courmontagne, P., Cura, V., Brimer, N., Babah, K. O., Ansari, T., Muller, I., Stote, R. H., Cavarelli, J., Vande Pol, S., Travé, G. Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. *Science* **339**, 694-698 (2013).

38. Dunbrack, Jr., R. L., Cohen, F. E. Bayesian statistical analysis of protein side-chain rotamer preferences. *Prot. Sci.* **6**, 1661-1681 (1997).

39. Jemth, P., Karlsson, E., Vögeli, B., Guzovsky, B., Andersson, E., Hultqvist, G., Dogan, J., Güntert, P., Riek, R., Chi, C. N. Structure and dynamics conspire in the evolution of affinity between intrinsically disordered proteins. *Sci. Adv.* **4**, eaau4130 (2018).

40. Waters, L., Yue, B., Veverka, V., Renshaw, P., Bramham, J., Matsuda, S., Frenkiel, T., Kelly, G., Muskett, F., Carr, M., Heery, D. M. Structural diversity in p160/CREB-binding protein coactivator complexes. *J. Biol. Chem.* **281**, 14787-14795 (2006).

41. Fersht, A. R., Daggett, V. Protein folding and unfolding at atomic resolution. *Cell* **108**, 1-20 (2002).

42. DeLano, W. L. Unraveling hot spots in binding interfaces: progress and challenges. *Curr. Opin. Struct. Biol.* **12**, 14-20 (2002).

43. Matouschek, A., Kellis, J. T., Serrano, L., Fersht, A. R. Mapping the transition state and pathway of protein folding by protein engineering. *Nature* **340**, 122-126 (1989).

44. Fuxreiter, M., Tompa, P. Fuzzy complexes: a more stochastic view of protein function. *Adv. Exp. Med. Biol.* **725**, 1-14 (2012).

45. Dogan, J., Mu, X., Engström, Å., Jemth, P. The transition state structure for coupled binding and folding of disordered protein domains. *Sci Rep.* **3**, 2076 (2013).

46. Karlsson, E., Andersson, E., Dogan, J., Gianni, S., Jemth, P., Camilloni, C. A structurally heterogeneous transition state underlies coupled binding and folding of disordered proteins. *J. Biol. Chem.* **294**, 1230-1239 (2019).

47. Ganguly, D., Zhang, W., Chen, J. Synergistic folding of two intrinsically disordered proteins : searching for conformational selection. *Mol. BioSyst.* 8, 198-209 (2012).

48. Schneider, R., Maurin, D., Communie, G., Kragelj, J., Hansen, D. F., Ruigrok, R. W. H., Jensen, M. R., Blackledge, M. Visualizing the molecular recognition trajectory of an intrinsically disordered protein using multinuclear relaxation dispersion NMR. *J. Am. Chem. Soc.* **137**, 1220-1229 (2015).

49. Lonard, D. M., O'Malley, B. W. Molecular pathways: targeting steroid receptor coactivators in cancer. *Clin. Cancer Res.* **22**, 5403-5407 (2016).

50. Breen, M. E., Mapp, A. K. Modulating the masters: chemical tools to dissect CBP and p300 function. *Curr. Opin. Chem. Biol.* **45**, 195-203 (2018).

51. Lasko, L. M. et al. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. *Nature* **550**, 128-132 (2017).

52. Dang, C. V., Reddy, E. P., Shokat, K. M., Soucek, L. Drugging the 'undruggable' cancer targets. *Nat. Rev. Cancer* **17**, 502-508 (2017).

53. Mendel, D., Ellman, J., Schultz, P. G. Protein biosynthesis with conformationally restricted amino acids. *J. Am. Chem. Soc.* **115**, 4359-4360 (1993).

54. Chin, J. W. Expanding and reprogramming the genetic code. *Nature* **550**, 53-60 (2017).

Fig. 1. Backbone α-methylation to stabilize helical conformations in intrinsically disordered proteins. (a) Disordered conformations adopt secondary structures upon incorporation of conformationally constrained amino acids. (b) Domain organization of CBP/p300 and ACTR (or SRC3), which interact with each other via NCBD (in orange) and AD1 (in violet) domains. For clarification of domain abbreviations, see refs[21,22]. (c) Sequence of [1040-1086]-fragment of ACTR that binds to NCBD of CBP/p300 with residues that were replaced by α-methylated congeners in green. Additional methyl groups attached at α-carbon constrain backbone (φ,ψ)-dihedral angles to values that correspond to 3_{10}/α-helix (green circle) in lower, left quadrangle of the Ramachandran plot.

Fig. 2. Thermodynamic dissection of the effect of α-methylation on binding of AD1-ACTR and NCBD by ITC measurements. (a) Chemically synthesized variants of AD1-ACTR are arranged along *x*-axis according to their binding affinities to NCBD (from low to high). The corresponding sites of α-methylation and numbering of AD1-ACTR variants are listed below. In *y*-axis Gibbs free energy of binding for wild type is subtracted from the corresponding values for each variant (ΔΔG). All studied complexes were additionally characterized by circular dichroism spectroscopy (Supplementary Fig. 3, Fig. 4b and Supplementary Table 6). The stabilities of the selected complexes determined by thermal denaturation (Supplementary Fig. 5 and Supplementary Table 4) are in agreement with the ITC data. (b) Gibbs free energy (ΔG), enthalpy (ΔH) and entropy (-TΔS) of complex formation (at T = 304 K) between α-methylated variants of AD1-ACTR and NCBD. The respective values of ΔH and ΔS can be fitted with a linear regression (ΔH = α + β*x*ΔS), where the slope β or "compensation temperature"[32] is 340 ± 7 K. Different magnitudes of enthalpy-entropy changes reflect the modification of free energy surface of coupled binding and folding upon α-methylation[31].

Fig. 3. α-Methylation enhances helical structures in free ACTR activation domain. (a) $^{13}C^{\alpha}$ secondary chemical shift analysis indicates higher helical content in the proximity to the sites of incorporated α-methylated amino acids 1055 and 1076 (indicated by black dashed line). Furthermore, substitution at 1055 position results in higher population of helical structure at N-terminus (segment 1045-1054). (b) C^{α} transverse relaxation rates (R_2) display increased values upon α-methylation, especially in double methylated [1055meLeu;1076meLeu]AD1-ACTR variant, suggesting the presence of conformational exchange between disordered and structured states. The R_2 measurement uncertainties correspond to ~10% of the R_2 values and are within the dimension of the circles in the plot. The average R_2 value calculated for all residues in WT AD1-ACTR is included as pink dashed line in all three panels to highlight the overall R_2 increase observed upon α-methylation.

Fig. 4. Properties of the complex with the highest binding affinity. (a) An X-ray structure of NCBD bound to [1055meLeu;1076meLeu]AD1-ACTR (PDB ID: 6SQC). To facilitate the crystallization, NCBD was fused to maltose-binding protein (MBP) depicted in gray in the leftmost panel. The NCBD (in gold) and [1055meLeu;1076meLeu]AD1-ACTR (in purple-blue) have significantly higher thermal B-factors (thicker tube) than MBP reflecting the "fuzziness" of the complex. Enlarged structure of the complex in the middle illustrates the arrangement of six α-helices and the positions of α-methylated Leu residues (1055meLeu and 1076meLeu). Both residues adopt α-helical conformations (corresponding helices are on the right). The side chain of 1055meLeu adopts [*trans* (*t*, χ_1 = -167.4º), *trans* (*t*, χ_2 = 153º)] rotamer conformation, while 1076meLeu has its side chain in [*gauche-* (*g-*, χ_1 = -59.3º), *trans* (*t*, χ_2 = 137º)] conformation[38]. Dihedral angles Cγ-Cβ1-Cα-Cβ2(methyl) are -35.4º and 62.3º for meLeu1055 and meLeu1076, respectively, allowing α-methyl groups to avoid steric clashes with isopropyl side chains (stereochemical Newman projections are provided in Supplementary Fig. 13). (b) Root-mean square fluctuations (RMSF) in MD simulations (GROMOS, 200 ns) of three complexes (wild type in black, [1055meLeu]AD1-ACTR/NCBD in red and [1055meLeu;1076meLeu]AD1-ACTR/NCBD in green) showing that α-methylation rigidifies motions in both AD1-ACTR and NCBD (see Supplementary Figs. 16 and 17 for an additional analysis). (c) The corresponding Ramachandran plots depict well-defined helical distributions of (φ,ψ)-dihedral angles for α-methylated residues 1055meLeu and 1076meLeu in contrast to less defined conformations for non-methylated Leu residues in the corresponding complexes.

Fig. 5. α-Methylation enhances binding of ACTR activation domain both to NCBD and full length (270 kDa) CBP. (a,b) Surface plasmon resonance (SPR) binding curves of NCBD to wild type ACTR activation domain and double α-methylated [1055meLeu;1076meLeu]AD1-ACTR variant at 20 °C. Steady state analysis reveals ~10-times enhanced binding constant for dimethylated variant (see Supplementary Figs. 18, 19 and Supplementary Tables 15, 16 for data at four other temperatures and the estimated values of k_{on}, k_{off} and K_D). (c,d) The same effect is observed for full length 270 kDa CBP with apparent K_D values indicating an order of magnitude improvement for the α-methylated [1055mL;1076mL]AD1-ACTR-variant: ~60 nM versus 1.2 μM for wild-type (Supplementary Fig. 20; complementary fluorescence polarization measurements are consistent with SPR data, see Supplementary Fig. 21; negative control with weak-binding [1064mL;1071mL] variant shown in Supplementary Fig. 22).

Enhancing binding affinity of an intrinsically disordered protein by α-methylation of key amino acid residues

Valentin Bauer[1†], Boris Schmidtgall[1†], Gergő Gógl[2#], Jozica Dolenc[3], Judit Osz[2], Yves Nominé[2#], Camille Kostmann[2#], Alexandra Cousido-Siah[2#], André Mitschler[2#], Natacha Rochel[2], Gilles Travé[2#], Bruno Kieffer[2] and Vladimir Torbeev[1]*

[1] Institut de Science et d'Ingénierie Supramoléculaires (ISIS), International Center for Frontier Research in Chemistry (icFRC), University of Strasbourg, CNRS (UMR 7006), Strasbourg, France
[2] Department of Integrated Structural Biology, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM (U964), University of Strasbourg, CNRS (UMR 7104), Illkirch, France
[3] Chemistry | Biology | Pharmacy Information Center, ETH Zurich, Zurich, Switzerland

* Correspondence should be addressed to V. T. (torbeev@unistra.fr)
† These authors equally contributed to this work
# Équipe Labellisée Ligue 2015

Table of contents:

Supplementary Materials and Methods

## 1. Chemical synthesis of peptides and protein domains

Reagents: Solvents, chemicals and reagents were purchased from commercial sources. Fmoc-α-*L*-amino acids and resins for solid-phase peptide synthesis were purchased from Aapptec, Bachem or Iris Biotech, diisopropylethylamine (DIEA) and piperidine from Sigma-Aldrich, trifluoroacetic acid (Biograde) from Halocarbon. Fmoc-protected α-methylated *L*-amino acids were purchased from OKeanos Tech. (China), Iris Biotech and Bachem. The coupling reagents O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), N,N'-diisopropylcarbodiimide (DIC) and ethyl cyano(hydroxyimino)acetate (OxymaPure) were obtained from Iris Biotech. Fmoc-Lys(Biotin), Fmoc-NH-(PEG)$_3$-COOH and Fmoc-NH-(PEG)$_5$-COOH were purchased from Iris Biotech, and 5-(iodoacetamido)fluorescein from Santa Cruz biotechnology.

Peptide synthesis: The peptide-$^\alpha$thioesters and cysteinyl-peptides were synthesized according to the previously described methods of SPPS and conjugated via native chemical ligation as reported[1-4]. In this work, in addition to two-segment ligation approach, protein domains were synthesized on solid phase in full length (47 residues) using microwave-assisted automated synthesis. The procedures for this approach are detailed below.

Polypeptides corresponding to [1040-1086]-fragment of the ACTR (numbering as in *Nature* **415**, 549-553 (2002), which corresponds to [1045-1091]-fragment of sequence Q9Y6Q9 (NCOA3_HUMAN) in UniProtKB) and [2066-2112]-fragment of CBP (CREB-binding protein, UniProtKB - P45481 (CBP_MOUSE)) were assembled using a Liberty Blue microwave-assisted automatic synthesizer (CEM Corporation, USA) on either 0.05, 0.1 or 0.2 mmol scale. Variants of the [1040-1086]-fragment of the ACTR containing α-methylated amino acids were synthesized analogously. The following protocol describes a synthesis on 0.1 mmol scale using Fmoc-Lys(Boc)-Wang polystyrene resin, 100-200 mesh with 0.47 mmol/g loading. To perform standard microwave-assisted coupling reactions the coupling reagent DIC (1 mL, 0.5 M), the activator OxymaPure (0.5 mL, 1 M) and the amino acid (2.5 mL, 0.2 M) were added to the resin and the suspension was treated at 90 °C for 2 min (170 W for 15 s, 30 W for 110 s). For some of the amino acids special conditions were used to achieve complete coupling. For Arg as well as for β-branched amino acids the coupling under standard microwave conditions was performed twice. The coupling of His was performed twice at 50 °C for 10 min (0 W 120 s, 35 W 480 s). The coupling of α-methylated amino acids (0.2 M solution) was performed at 90 °C for 4 min. Fmoc-deprotections were performed by adding 20% (v/v) 4-methylpiperidine (3 mL) to the resin and treating the suspension for 1 min at 90 °C (155 W 15 s, 32 W 50 s).

The peptides with sequences *(H)*-DERALLDQLHTLLSN-*(NH₂)* and *(H)*-DERALLDQLHT-meLeu-LSN-*(NH₂)* (meLeu = α-methyl-*L*-leucine) corresponding to [1045-1059]-fragment of ACTR were also assembled by a microwave-assisted SPPS using Fmoc-Rink-Amide-AM polystyrene resin with 0.71 mmol/g loading. Shorter peptides corresponding to the LXXLL motif of AD1-ACTR with two flanking additional amino acids, *(H)*-QLHTLLS-*(NH₂)* and *(H)*-QLHT-meLeu-LS-*(NH₂)* were prepared in the same manner.

Biotinylated peptides needed for surface plasmon resonance (SPR) measurements were synthesized on a 0.05 mmol scale using Rink-Amide ChemMatrix resin (0.49 mmol/g loading). First, Fmoc-Lys(Biotin) was coupled to the resin followed by Fmoc-NH-(PEG)₃-COOH (Iris Biotech, art. no.: PEG4370, chemical structure depicted below) and subsequently three glycine residues. Then, the actual sequence of the corresponding AD1-ACTR variant was assembled.

Fluoresceine-labeled AD1-ACTR peptides: cysteinyl-peptides were synthetized using microwave-assisted peptide synthesis as described above. The N-terminal cysteine was separated from the peptide sequence using a (PEG)₅ linker. After purification on a C4 Jupiter column (same method as other AD1-ACTR, see on p.4) Cys-(PEG)₅-WT-AD1-ACTR and Cys-(PEG)₅-[1055meLeu;1076meLeu]AD1-ACTR were labeled using the thiol reactive 5-(iodoacetamido)fluorescein. To do so, two solutions were prepared. First 2 mg of peptide (1 eq, 3.7×10^{-7} moles) were dissolved in 300 µL of 100 mM NaHCO₃ 5 mM TCEP at pH 7.5. Then, protected from light, 1 mg of 5-(iodoacetamido)fluorescein (5 eq) were dissolved in 300 µL of anhydrous DMF. The two solutions were mixed, quickly stirred and allowed to react for 10 min at room temperature. The reaction mixture was further purified on a C4 Jupiter column (same method as other AD1-ACTR, see on p.4) and pure fractions were combined and lyophilized yielding a green-yellowish powder (1.3 mg, 59%). The structure of the dye and spacer are shown below:

Analytical HPLC: Analytical reversed phase HPLC of all peptides and proteins was performed on a Dionex Ultimate 3000 (Thermo Fisher) equipped with a UV detector, a column heater set to 40 °C and an autosampler. Analyzes were performed on a Kinetex EVO C18 column (Phenomenex, particle size 2.6 μm, pore size 100 Å, dimensions 50 × 2.1 mm) or a Kinetex XB C18 column (Phenomenex, particle size 2.6 μm, pore size 100 Å, dimensions 50 × 2.1 mm) at a flow rate of 1 mL/min and a gradient of 2-50% of eluent B (0.08% TFA in acetonitrile) in eluent A (0.1% TFA in H$_2$O) within 4 min.

Preparative HPLC: Preparative reversed phase HPLC was performed on a Shimadzu instrument equipped with a CBM-20A communication module, a SPD-M20A UV detector, a SIL-10AP autosampler and a FRC-10A fraction collector.

Wild type AD1-ACTR and its α-methylated variants were injected onto a Jupiter C4 column (Phenomenex, particle size 10 μm, pore size 300 Å, dimensions 250 × 21 mm) at a flow rate of 10 mL/min and a gradient of 10-46% of eluent B (0.08% TFA in acetonitrile) in eluent A (0.1% TFA in H$_2$O) within 70 min. After purification, pure fractions were identified by analytical HPLC and LC/MS, combined and lyophilized.

NCBD protein was purified two times on a Jupiter C4 column (Phenomenex, particle size 10 μm, pore size 300 Å, dimensions 250 × 21 mm) at a flow rate of 10 mL/min and a gradient of 10-40% of eluent B (0.08% TFA in acetonitrile) in eluent A (0.1% TFA in H$_2$O) within 85 min. After purification, pure fractions were identified by analytical HPLC and LC/MS, combined and lyophilized.

Peptides *(H)*-DERALLDQLHTLLSN-*(NH$_2$)* and *(H)*-DERALLDQLHTL-meLeu-SN-*(NH$_2$)* (meLeu = α-methyl-*L*-leucine) and shorter LXXLL motif containing peptides (see above) were purified on a C18 column (Phenomenex, particle size 10 μm, pore size 300 Å, dimensions 250 × 21.00 mm) at a flow rate of 10 mL/min and a gradient of 5-30 % of eluent B (0.08% TFA in acetonitrile) in eluent A (0.1% TFA in H$_2$O) within 40 min. After purification, pure fractions were identified by analytical HPLC and LC/MS, combined and lyophilized.

Mass-spectrometry: Peptide masses were determined using a LC/MS instrument containing a Thermo Scientific Accela UHPLC (Hypers II GOLD column, 50 × 2.1 mm, 1.9 μm) integrated with a Thermo Scientific LCQ Fleet ion trap. Deconvolution of experimental data was performed using the Zscore algorithm with the help of MagTran 1.03 software.

Supplementary Tables 1 and 2 provide the list of sequences of the peptides studied in this work and the corresponding mass-spectrometry data.

2. Protein expression

Maltose binding protein (MBP)-NCBD: MBP-NCBD construct was over-expressed in *E. coli* BL21(DE3) overnight at 16 °C. The construct was purified by amylose affinity chromatography in buffer A (50 mM Tris pH 8, 400 mM NaCl, 1 mM DTT). In order to remove soluble oligomers, the purified sample was ultracentrifuged overnight at 40,000 RPM in a swing SW41 rotor (Beckman) at 4 °C. Then the resulting MBP-NCBD sample was concentrated and loaded onto a Superdex 200 pg HiLoad 26/60 gel filtration column (GE Healthcare) equilibrated in buffer A.

CREB-binding protein (CBP): The full length hsCBP (1-2442 aa) cloned into pDEST10 plasmid with N-terminal His-tag and C-terminal Flag and Myc-tag was a kind gift of Dr. P. Tompa (Flanders Institute for Biotechnology, Belgium). The protein was expressed in Sf21 insect cells for 48 h. To avoid the intracellular proteolytic degradation, 1 tablet of Roche cOmplete EDTA free protease inhibitor dissolved in ultrapure sterile water was added to the expression culture after 24 h of culture. The purification of the protein was performed as described in Bekesi et al.[5] with small modifications. The cell pellet of 1 L expression culture was resuspended in 50 mM Tris pH 7.5, 300 mM NaCl, 2 mM $MgCl_2$, 5 % glycerol, 1 mM DTT, 5 μg/ml DNase I, 5 μg/ml RNase A. The cell suspension was homogenized in Dounce homogenizer, sonicated (2 min, 40% amplitude, 0.5 cycle, in ice) and homogenized. The lysate was ultracentrifuged for 1 h at 125 000 g and the supernatant was filtered with 0.45 μM pore-size filter. The purification was performed in 3 steps: a Ni-affinity using Ni-cOmplete resin (Roche), a Flag affinity step in batch chromatography followed by a size-exclusion chromatography on Superose 6 Increase column (GE Healthcare Life Sciences) using Akta systems and 50 mM Tris pH 7.5, 300 mM NaCl, 1 mM TCEP buffer. All steps were carried out in presence of the protease inhibitors: Roche cOmplete EDTA free, pepstatin A, bestatin, Pefabloc and E64, 25 μM Pefabloc and 2 μg/ml E64, and performed at 4°C. The SDS PAGE confirmed molecular weight of recombinant CBP:

8 % SDS-PAGE

3. Isothermal titration calorimetry (ITC)

Most ITC measurements were performed according to the previously described procedure using an iTC 200 microcalorimeter (GE Healthcare)[1]. To analyze and visualize the data NITPIC, SEDPHAT/ITCsy, and GUSSI software were used[6-8]. For each AD1-ACTR variant two titrations and two control experiments (*i.e.,* titration of buffer into buffer, and the NCBD into buffer) were performed. The data depicted in Supplementary Fig. 1 (panels 1-36) show only one representative titration with baseline subtracted. The observed positive signal on the right side of the titration curves is due to the slight buffer mismatch and heat of NCBD dilution that were corrected by subtraction of control titrations. For each AD1-ACTR variant the two recorded titration curves were fitted globally. The error estimation for K_D and ΔH values were $\pm 20\%$ and $\pm 5\text{-}8\%$, respectively.

For weak binding AD1-ACTR variants such as [1064mL;1071mL], as well as *(H)-*DERALLDQLHTLLSN-*(NH₂)*, *(H)*-DERALLDQLHTL-meLeu-SN-*(NH₂)* (meLeu = α-methyl-*L*-leucine), *(H)*-QLHTLLS-*(NH₂)* and *(H)*-QLHT-meLeu-LS-*(NH₂)* peptides a PEAK ITC microcalorimeter (Malvern Instruments) was used. To avoid aggregation of NCBD protein at high concentrations, 25-60 μM of NCBD was in a sample cell (titrant) and the corresponding ACTR derived variants were in the syringe (titrators) at 250-600 μM concentrations. The solutions of AD1-ACTR variants were dialyzed for 48 h before measurements against a 10 mM Tris, 50 mM NaCl, 0.05% (w/v) NaN_3 buffer at pH 6.9 and room temperature. The titration parameters were set as following, temperature 31 °C, reference power 10 μcal/s, feedback=high, stirring speed 750 RPM, initial delay 60 s, first injection 0.4 μL in 0.8 s and the remaining 19 injections were 2 μL in 4 s with 120 s of spacing. The initial fitting was performed using the analysis software from Malvern with subtraction of three control experiments (*i.e.,* titration of buffer into buffer, buffer into NCBD solution and the ACTR variants into buffer) and a correction of concentration taking into account precise concentration measurements by analytical HPLC using calibration curve at OD 220 nm. For [1064mL;1071mL]AD1-ACTR analogue previously used fitting protocol was applied to report the thermodynamic parameters listed in Supplementary Table 3. The inversion of the analytes and method of fitting are not significantly affecting the thermodynamics parameters: the control titrations of the WT AD1-ACTR and [1055mL]AD1-ACTR variants were performed using these settings resulting in similar K_D values of 0.208 μM and 0.072 μM compared to values of 0.204 μM[1] and 0.075 μM (Supplementary Table 3), obtained by the first method.

4. Circular dichroism (CD)

CD spectra were recorded using a J-1500 (Jasco) spectrophotometer. All samples were prepared in a quartz cuvette (thickness of 1 mm and a volume of 300 μL). For every measurement protein or protein

complexes were dissolved in a buffered solution (20 mM phosphate, pH 7.4) at a concentration of 25 µM. For data collection the following parameters were set: scan range 280-185 nm, band width 1.00 nm, scanning speed 100 nm/min, data pitch 0.1 nm. Every CD curve was obtained by averaging of 5 scans and subtracting the background signal. The data are depicted in Supplementary Fig. 3.

The thermal stability of complexes of several AD1-ACTR variants with NCBD (concentration of complex 50 µM) was evaluated by monitoring the ellipticity at 222 nm as a function of temperature from 20 to 90 °C. Rate of heating / cooling was 1 °C/min. The thermal denaturation was found to be highly reversible. The thermal denaturation curves are depicted in Supplementary Fig. 5 and the apparent melting temperatures are listed in Supplementary Table 4.

For free AD1-ACTR protein variants, the ratio of ellipticities ($\theta_{222}/\theta_{199}$) was calculated in order to compare their helical contents[9] (Supplementary Fig. 4a). For their complexes with NCBD, the other ratio ($\theta_{222}/\theta_{208}$) was derived (Supplementary Fig. 4b), which may serve as a readout of helix-helix interactions[10]. All obtained values are summarized in Supplementary Tables 5 and 6, respectively.

5. NMR measurements

All NMR spectra were recorded on a 700 MHz Bruker spectrometer equipped with TCI cryo-probe at 304 K in 3 mm NMR tubes. The proton frequencies were referenced using DSS (2,2-dimethyl-2-silapentane-5-sufonate) as external reference and carbon frequencies were referenced using the indirect method[11].

Sample preparation: Proteins samples were obtained by dissolving the appropriate amount of each protein in 200 µL 90 % H_2O, 10 % D_2O, 20 mM sodium phosphate, 0.05 % NaN_3 buffer at pH 7.2. The exact concentrations were measured by analytical HPLC using a calibration curve and adjusted to 1.4 mM. For NMR experiments in D_2O, 200 µL of the samples described above were lyophilized for at least 48 h. The resulting powder was then re-dissolved in 200 µL of pure D_2O just before the experiment.

Spectra acquisition: The ^{1}H-^{13}C HSQC spectra were recorded using the gradient-selected coherence transfer pulse-sequence of the Bruker standard library. A resolution of 2 and 12 Hz in the ^{1}H and ^{13}C dimensions, respectively, were used with relaxation delays set to 1.2 s for a total experimental time of approximately 3.5 h. 60 kHz Chirp pulses of 500 µs and a B_1-field of 8 kHz were used for ^{13}C resonance inversion.

The measurements of the ^{13}C R_1 and R_2 relaxation rates were performed using refocused ^{1}H-^{13}C HSQC type experiments incorporating ^{13}C relaxation time[12]. For the R_1 relaxation experiment proton decoupling was applied with 180 degree pulses every 2.5 ms. The following T_1 delays were used: 10, 50, 100, 200, 300, 400, 600, 800 ms. Additional points (50, 500 ms) were recorded for wild type and [1055meLeu]AD1-

ACTR variant samples to estimate the experimental uncertainty on peak volumes. For the R_2 relaxation, a CPMG pulse sequence was used during the carbon relaxation time with 300 μs half-echo delay and a B_1-field of 10 kHz. The T_2 delays were 35, 70, 140, 176, 211, 246, 317, 387 ms. Additional points (105, 211 ms) were recorded for wild-type and [1055mL]AD1-ACTR variant to estimate the experimental uncertainty on peak volumes. The relaxation delay was set to 2.5 s and total acquisition time was approximately 25 hours for each set of relaxation experiments.

The ^{1}H homonuclear TOCSY and NOESY experiments were recorded using 4096 and 600 points in the direct and indirect dimensions, respectively. The spectral width was set to 7.8 kHz and the relaxation delay to 2 s. The mixing times were 80 ms and 500 ms for the TOCSY and the NOESY, respectively. A B_1-field of 9 kHz was used for the TOCSY spin-lock. ^{1}H-^{13}C HSQC-TOCSY were recorded with a resolution of 4 and 24 Hz for the ^{1}H and ^{13}C dimensions, respectively, a relaxation time of 1.2 s and a TOCSY mixing time of 80 ms (B_1-field of 9 kHz) for a total experiment time of 14 h. The ^{1}H-^{13}C HMBC experiment was recorded with carrier frequency centered on the carbonyl resonances (174 ppm) to correlate the carbonyl with the adjacent Hα proton frequencies using the gradient-selected coherence transfer pulse-sequence of the Bruker standard library. The delay for long-range magnetization transfer was set to 89.3 ms ($^2J_{CO-H\alpha}$ 5.6 Hz). The resolution were 4 Hz and 7 Hz for the proton and carbon dimensions, respectively. The relaxation time was set to 2 s for a total measurement time of 32 h.

Manual assignment of ^{1}H-^{13}C HSQC: Spin systems were manually identified using ^{1}H-^{1}H TOCSY (80 ms mixing time) and the sequential assignment was based on the inter-residue correlations identified in the ^{1}H-^{1}H NOESY (500 ms mixing time). Cα carbon assignments were obtained using high-resolution ^{1}H-^{13}C HSQC experiment. Ambiguities in the ^{1}H-^{13}C HSQC were solved using ^{1}H-^{13}C HSQC-TOCSY (80 ms mixing time) experiment. In two cases (N1058 and N1078) HMBC experiment was used to resolve the ambiguities of the assignment. When the WT AD1-ACTR protein was fully assigned, the chemical shifts being mostly the same, except for some residues, were used to assign the signals of [1055meLeu] and [1055meLeu;1076meLeu] AD1-ACTR analogues.

Data processing was performed using TopSpin software 2.1. All spectral analysis including frequency assignments and relaxation rate measurements were performed using ccpNmr (version 2.4.2)[13]. For relaxation measurements, time dependent evolutions of the peak intensities were fitted using a single exponential model and the estimate of the uncertainty of the fitted parameters was obtained using the covariance method implemented in ccpNmr.

Chemical shifts for wild-type AD1-ACTR, [1055meLeu]AD1-ACTR and [1055meLeu;1076meLeu]AD1-ACTR analogues are listed in Supplementary Tables 7-9. Relaxation rates R_1 and R_2 and experimental uncertainties are tabulated in Supplementary Tables 10 and 11.

Secondary chemical shifts: POTENCI program[14] was used to create a neighbor-corrected list of the random coil chemical shifts of the wild-type AD1-ACTR sequence including the effect of temperature, pH and ionic strength to be subtracted from the experimental chemical shifts.

6. X-ray crystallography

Crystallization, data collection and structure refinement: The NCBD-ACTR complexes were reconstituted by mixing MBP-NCBD construct and synthetic wild-type AD1-ACTR, [1055meLeu] or [1055meLeu;1076meLeu] in a 1:1 stoichiometric ratio in buffer B (10 mM Tris pH 8, 100 mM NaCl, 1 mM DTT, 5 mM Maltose) and concentrated to 85 mg/mL prior to crystallization. Crystallization conditions were screened using commercially available kits (Qiagen, Hampton Research, Emerald Biosystems) by the sitting-drop vapor-diffusion method in 96-well MRC 2-drop plates (SWISSCI), using a Mosquito robot (TTP Labtech). After 3 weeks a crystal grew for a complex of MBP-NCBD with [1055meLeu;1076meLeu] variant in a drop made from 200 nL of protein solution at 85 mg/mL and 100 nL of reservoir solution containing 20% polyethylene glycol 6000, 100 mM Tris pH 8 and 10 mM $ZnCl_2$. The crystals were flash-cooled in a cryoprotectant solution containing 30% Ethylene Glycol and stored in liquid nitrogen.

X-ray diffraction data were collected up to a resolution of 2.28Å at the Synchrotron Swiss Light Source (SLS) (Switzerland) on the X06DA beamline and processed with the program XDS[15]. The crystal structure was solved by molecular replacement with a high resolution crystal structure of MBP (PDB entry 5H7Q[16]) using Phaser[17] and structure refinement was carried out with PHENIX[18]. Building of the unnatural meLeu residues were achieved using eLBOW[19]. TLS refinement was applied during the refinement[20]. The crystallographic parameters and the statistics of data collection and refinement are shown in Supplementary Table 12. The refined model and the structure factor amplitudes have been deposited in the PDB under PDB entry: 6SQC.

7. Molecular dynamics (MD) simulations

Molecular dynamics simulations were carried out with the GROMOS biomolecular simulation package[21,22] and the GROMOS force-field parameter set 54A7[23,24]. The initial coordinates for AD1-ACTR/NCBD, [1055meLeu]AD1-ACTR/NCBD and [1055meLeu;1076meLeu]AD1-ACTR/NCBD complexes were derived from the solution NMR structure of the ACTR-NCBD complex (PDB ID 1KBH, model 1) and sequence has been matched to the experimentally studied sequence from this work. In the NCBD sequence methionine 2098 was replaced by norleucine. Each complex was solvated in approximately 8400 simple point charge (SPC)[25] water molecules. Rectangular periodic boundary conditions were used and 26 Na^+ and 24 Cl^- ions were added to each simulation box to neutralize the negative charge and to mimic the ionic strength of 0.15 M. The dimensions of the box were determined by

a minimum solute-wall distance of 1.2 nm and a minimum solute-solvent atom-atom distance of 0.23 nm. In order to relax unfavorable contacts between atoms of the solute and the solvent, the systems were relaxed by performing a steepest-descent energy minimization with harmonic positional restraints on all solute atoms (force constant 2.5×10^4 kJ mol^{-1} nm^{-2}), followed by an equilibration period of 1 ns in which the strength of the positional restraints was gradually released from 2.5×10^4 to 0.0 kJ mol^{-1} nm^{-2}, and the temperature was raised from 60 to 300 K. Initial velocities for the MD simulations were taken from a Maxwell–Boltzmann distribution. Solvent and solute were weakly coupled to separate temperature baths[26] with a relaxation time of 0.1 ps. After equilibration, the systems were also coupled to a pressure bath[26] with a relaxation time of 0.5 ps and an isothermal compressibility of 0.4575×10^{-3} (kJmol^{-1}nm^{-3})$^{-1}$. Bond lengths of the solute and the geometry of the solvent molecules were constrained using the SHAKE algorithm[27] with a relative geometric tolerance of 10^{-4}, so the leapfrog integration time step could be set to 2 fs. The non-bonded van der Waals and electrostatic interactions were calculated using a triple-range cutoff scheme. Nonbonded interactions were truncated at a distance of 1.4 nm and recalculated every time step in the range 0.0-0.8 nm and every five time steps in the range 0.8-1.4 nm. The long-range electrostatic interactions beyond the outer cutoff of 1.4 nm were represented by a reaction field[28] with a relative dielectric permittivity of 61 for water[29]. The motion of the center of mass was removed every 2 ps. The simulations were carried out for 200 ns at a constant pressure of 1 atm and a constant temperature of 300 K.

The coordinate trajectories were saved at 1 ps intervals and were analyzed using the GROMOS++ set of programs[30]. The first 50 ns of every simulation were considered as equilibration time and were omitted from the analysis. Atom-positional root-mean-square deviation (RMSD) and atom-positional root-mean-square fluctuations (RMSF) were calculated for the backbone atoms N, C, O and Cα using the energy-minimized initial structure as a reference. Conformational clustering analysis was performed with the approach of Daura et al.[31] using as a criterion a backbone atom-positional RMSD of less than 0.2 nm.

8. Biomolecular interaction analysis by Surface Plasmon Resonance (SPR)

The SPR measurements were performed on a Biacore T200 instrument (GE Healthcare - Biacore). Kinetics of NCBD binding to WT AD1-ACTR as well as to [1055meLeu;1076meLeu]AD1-ACTR, [1076meLeu]AD1-ACTR and [1055meLeu]AD1-ACTR variants were measured at five different temperatures (20, 22, 25, 27 and 31 °C). The buffer consisted of 10 mM HEPES, 500 mM NaCl and 0.005% (v/v) 10% P20 surfactant (GE Healthcare) at pH 7.5. The capture of biotinylated peptides on the chip was performed with the Biotin CAPture kit, Series S (GE Healthcare-Biacore). The oligo-streptavidin diluted 5 times in the running buffer was injected on all 4 channels at flow rate 2 µL/min for 300 sec. The first channel was always kept as a reference for subtraction of non-specific binding of NCBD to the chip surface. On the remaining 3 channels biotinylated AD1-ACTR variants at a concentration of 100 nM were injected at a

flow rate of 20 µL/min for 10 sec yielding around 25 to 35 RU. For regeneration between each sensogram recording a solution of 6 M guanidine-HCl, 250 mM NaOH was injected into all channels at 5 µL/min for 60 sec. The parameters for the binding measurement were set as follows: temperature varied from 20 to 31 °C, initial delay 60 sec, injection of NCBD 120 sec at 50 µL/min, dissociation 120 sec. NCBD solutions were prepared with a two-fold cascade dilution with a range of concentrations from 1 µM to 1.95 nM (10 dilutions).

Data analysis was performed using BiaEvaluation 3.2 software (GE Healthcare). After subtraction of the background signal from the reference channel, the curves were fitted assuming a simple 1:1 binding isotherm model. More advanced "two state" kinetic model involving a conformational change did not improve the fitting. The apparent dissociation constants (K_D), as well as association and dissociation kinetics (k_{on} and k_{off}) obtained upon fitting the data are provided in Supplementary Table 15. These values are listed in order to make a qualitative comparison (rather than quantitative) of binding properties by four different AD1-ACTR variants, given the complexity of coupled binding and folding and difficulties to obtain the exact fitting of the experimental curves.

Steady-state analysis was made to obtain dissociation constants and the corresponding experimental uncertainties (Supplementary Fig. 19)[32]. The steady-state binding (R_{eq}) was derived by averaging the signals at equilibrium. Subsequently, steady-state analysis using in-house Python scripts was performed by fitting the average signal R_{eq} as a function of analyte concentration, assuming a simple 1:1 interaction binding isotherm model, leading to 3 fitted parameters: the minimal signal (R_{min}), the maximum capacity of the surface (R_{max}) and the affinity (K_D). A Monte Carlo approach was further used in order to estimate the values and uncertainties of the R_{max} and K_D fitted parameters (Supplementary Table 16). This method consists of reproducing the fit using 1000 datasets in which noise fluctuations were introduced based on experimental uncertainty, and then the mean and the standard deviation of the fitted parameters were calculated.

The SPR measurements with full length 270 kDa CBP were also performed using Biotin CAPture kit, Series S (GE Healthcare-Biacore) on a Biacore T200 instrument (GE Healthcare - Biacore). The running buffer was 50 mM Tris, pH 7.5, 300 mM NaCl, 1 mM TCEP, 0.01% P20 supplemented with Roche Complete EDTA free protease inhibitor and the running temperature was set to 10 °C. First, the Biotin capture reagent was immobilized on the chip surface followed by the immobilization of the biotinylated ACTR variants (WT, [1055mL;1076mL]AD1-ACTR and [1064mL;1071mL]AD1-ACTR) as ligands. Interactions of the hCBP full length protein with the WT and AD1-ACTR analogues were analyzed in the manner of dose response using twofold dilution series of hCBP ranging from 200 to 0.75 nM. The association and dissociation phase were 100 s and the analyte flow rate 40 µl/min. For regeneration, a solution of 6 M guanidine-HCl, 250 mM NaOH was injected into all channels at 5 µL/min for 60 sec. After

subtracting the reference and buffer signal, the data were fit to a steady state binding model to define the apparent K_D.

Equilibrium signals were extracted from experimental SPR data for both systems and subsequently fitted with a 1:1 binding model. Since the data recorded for WT ACTR / hCBP interaction are so far from saturation, the fitting has been done in two steps: a first one by fitting the equilibrium data for the ACTR doubly methylated variant, leading, among others, to the maximum capacity R_{max} value; then a second step in which the previous R_{max} value has been used as forced parameter into the fit of the wild-type AD1-ACTR data, assuming that the saturation level is the same for both the wild type and the doubly methylated analogue (Supplementary Fig. 20).

9. Fluorescence polarization (FP) measurements

The fluorescein labeled AD1-ACTR (WT and [1055meLeu;1076meLeu] variant) was diluted at 5 nM in the assay buffer (25 mM Hepes pH 7.5, 150 mM NaCl, 1 mM TCEP, 0.05% Tween-20) and mixed with increasing concentration of hCBP (0.03-470 nM). The triplicates of the mixtures were transferred into 384 well black microplate (PS, F-bottom; Greiner Bio-one) and let incubate for 10 min at 25 °C in the dark. The FP was recorded by PHERAstar Plus (BMG LABTECH) at 25 °C, using excitation and emission filters of 485 and 520 nm, respectively. Graphpad Prism 8 software was used to calculate the dissociation constant (K_D) by fitting a curve with the one site binding model (Supplementary Fig. 21).

Supplementary Figures

Supplementary Fig. 1: Isothermal titration calorimetry of binding of AD1-ACTR variants to NCBD (consists of 36 panels on p. 13-21).

Panel 1: Binding of [S1043M;D1050E;T1054Q] AD1-ACTR to NCBD

Panel 2: Binding of [A1047G] AD1-ACTR to NCBD

Panel 3: Binding of [1048mL] AD1-ACTR to NCBD

Panel 4: Binding of [1049mL] AD1-ACTR to NCBD

Supplementary Fig. 1: Isothermal titration calorimetry of binding of AD1-ACTR variants to NCBD (continued from p. 13).

Panel 5: Binding of [1052mL] AD1-ACTR to NCBD

Panel 6: Binding of [1055mL] AD1-ACTR to NCBD

Panel 7: Binding of [1056mL] AD1-ACTR to NCBD

Panel 8: Binding of [1064mL] AD1-ACTR to NCBD

Supplementary Fig. 1: Isothermal titration calorimetry of binding of AD1-ACTR variants to NCBD (continued from p. 14).

Panel 9: Binding of [1072mA] AD1-ACTR to NCBD

Panel 10: Binding of [1077mL] AD1-ACTR to NCBD

Panel 11: Binding of [1080mA] AD1-ACTR to NCBD

Panel 12: Binding of [1082mA] AD1-ACTR to NCBD

Supplementary Fig. 1: Isothermal titration calorimetry of binding of AD1-ACTR variants to NCBD (continued from p. 15).

Panel 13: Binding of [1047mA;1072mA] AD1-ACTR to NCBD

Panel 14: Binding of [1047mA;1077mV] AD1-ACTR to NCBD

Panel 15: Binding of [1048mL;1076mL] AD1-ACTR to NCBD

Panel 16: Binding of [1048mL;1077mV] AD1-ACTR to NCBD

Supplementary Fig. 1: Isothermal titration calorimetry of binding of AD1-ACTR variants to NCBD (continued from p. 16).

Panel 17: Binding of [1048mL;1083mL] AD1-ACTR to NCBD

Panel 18: Binding of [1050mD;1071mL] AD1-ACTR to NCBD

Panel 19: Binding of [1050mD;1072mA] AD1-ACTR to NCBD

Panel 20: Binding of [1050mD;1076mL] AD1-ACTR to NCBD

Supplementary Fig. 1: Isothermal titration calorimetry of binding of AD1-ACTR variants to NCBD (continued from p. 17).

Panel 21: Binding of [1050mD;1077mV] AD1-ACTR to NCBD

Panel 22: Binding of [1055mA;1076mL] AD1-ACTR to NCBD

Panel 23: Binding of [1061mA;1071mL] AD1-ACTR to NCBD

Panel 24: Binding of [1061mA;1077mV] AD1-ACTR to NCBD

Supplementary Fig. 1: Isothermal titration calorimetry of binding of AD1-ACTR variants to NCBD (continued from p. 18).

Panel 25: Binding of [1064mL;1071mL] AD1-ACTR to NCBD

Panel 26: Binding of [1064mL;1076mL] AD1-ACTR to NCBD

Panel 27: Binding of [1064mL;1077mV] AD1-ACTR to NCBD

Panel 28: Binding of [1064mL;1083mL] AD1-ACTR to NCBD

Supplementary Fig. 1: Isothermal titration calorimetry of binding of AD1-ACTR variants to NCBD (continued from p. 19).

Panel 29: Binding of [1047mA;1055mL;1061mA] AD1-ACTR to NCBD

Panel 30: Binding of [1055mL;1076mL;1083mL] AD1-ACTR to NCBD

Panel 31: Binding of [1047mA;1050mD;1061mA;1076mL] AD1-ACTR to NCBD

Panel 32: Binding of [1047mA;1055mL;1061mA;1076mL] AD1-ACTR to NCBD

Supplementary Fig. 1: Isothermal titration calorimetry of binding of AD1-ACTR variants to NCBD (continued from p. 20).

Panel 33: Binding of [1047mA;1055mL;1076mL;1083mL] AD1-ACTR to NCBD

Panel 34: Binding of [1047mA;1061mA;1076mL;1083mL] AD1-ACTR to NCBD

Panel 35: Binding of [1047mA;1055mL;1061mA;1076mL;1083mL] AD1-ACTR to NCBD

Panel 36: Binding of [1047mA;1055mL;1061mA;1076mL;1083mL;1085mP] AD1-ACTR to NCBD

Supplementary Fig. 2. "Double mutant cycle" analysis for Gibbs free energy of complex formation for AD1-ACTR variants with two α-methylations according to relationship: $\Delta\Delta\Delta G = \Delta\Delta G_{variant-X} + \Delta\Delta G_{variant-Y} - \Delta\Delta G_{double-XY}$, where $\Delta\Delta G_{variant}$ is the variation in Gibbs free energy for a singly modified ACTR variant and $\Delta\Delta G_{double-XY}$ is the variation in Gibbs free energy for the doubly α-methylated protein. The numbering of protein variants is provided in Supplementary Table 1.

Supplementary Fig. 3. Circular dichroism (CD) spectra of AD1-ACTR variants and their complexes with NCBD. (a) Top panel: two control variants [S1043M;D1050E;T1054Q] (**2**) and [A1047G] (**3**) and protein analogues containing one α-methylated residue overlaid onto spectrum of wild-type (**1**); middle: analogues with two α-methylated amino acids, and bottom: containing multiple α-methylated residues. (b) Representative CD spectra of stabilized [1055mL] (**9**) (top panel), [1055mL;1076mL] (**34**) (middle panel), and destabilized [1064mL;1071mL] (**39**) (bottom panel) variants complexed with NCBD overlaid onto the corresponding spectrum of wild type complex.

a

b

Supplementary Fig. 4: (a) Ellipticity ratio $\theta_{222}/\theta_{199}$ of AD1-ACTR protein variants illustrating different helical content[9], which increases upon multiple α-methylation. (b) Ellipticity ratio $\theta_{222}/\theta_{208}$ of complexes of AD1-ACTR with NCBD suggesting non-identical secondary/tertiary structure in different complexes[10]. Note especially diminished values for analogues **13**, **21**, **35** and **39**, all containing 1071mL residue and the least stable in the library, although there is no straightforward correlation between helicity and stability. Different colors are used to highlight differences in values (blue correspond to lower values, red to higher values).

Supplementary Fig. 5: Thermal stability of AD1-ACTR/NCBD complexes evaluated by CD spectroscopy. Ellipticity at 222 nm was monitored as a function of temperature. The signal fully restores upon cooling after heating, *i.e.,* termal denaturation is reversible. Apparent melting points are provided in Supplementary Table 4 and are in agreement with relative order of thermodynamic stabilities (ΔG) of the protein variants obtained by isothermal titration calorimetry (ITC).

a

b

Supplementary Fig. 6: A comparison of ^{13}C-HSQC spectra in D$_2$O. (a) ^{13}C-HSQC spectra acquired in D$_2$O for wild type (WT) AD1-ACTR (in black) and two [1055meLeu] (in red) and [1055meLeu;1076meLeu] (in green) variants. (b) Pairwise superposition of the spectral regions corresponding to Cα-Hα correlations with the same color-coding as in (a).

Supplementary Fig. 7: A comparison of ^{13}C-HSQC spectra in D$_2$O. The excerpts of the ^{13}C-HSQC spectra of WT AD1-ACTR (in black), [1055meLeu] variant (in red) and [1055meLeu;1076meLeu] variant (in green) recorded in D$_2$O. The spectra are overlaid in a pairwise manner to illustrate the additional peaks for α-methyl groups of residues meLeu1055 and meLeu1076 in the corresponding proteins.

Supplementary Fig. 8: Superposition of the region of ^{13}C-HSQC spectra of WT AD1-ACTR (in black), [1055meLeu] variant (in red) and [1055meLeu;1076meLeu] variant (in green) recorded in D$_2$O shown to illustrate the changes of chemical shifts for CHα groups for residues Thr1054 and Val1077, which are in close proximity to helix-stabilizing meLeu1055 and meLeu1076, respectively.

Supplementary Fig. 9: Spin-lattice relaxation rates (R$_1$) are not perturbed significantly in two studied α-methylated [1055meLeu] (in red) and [1055meLeu;1076meLeu] (in green) variants of AD1-ACTR in comparison to wild type (in black). The vertical dashed lines in black indicate positions for α-methylation (1055 and 1076). The horizontal dashed lines (in magenta) in all three panels indicate the average R$_1$ value for WT AD1-ACTR. The R$_1$ values and the experimental uncertainties are listed in Supplementary Table 10.

Supplementary Fig. 10: A comparison of ^{13}C-HSQC spectra of complexes with NCBD. (a) Overlay of ^{13}C-HSQC spectra of complexes of NCBD with WT AD1-ACTR (depicted in black) and two analogues [1055meLeu] and [1055meLeu;1076meLeu] (in red and green, respectively). (b) The methyl region of the corresponding spectra showing that most of the structural differences in the complexes are for the aliphatic side-chains. The signal intensities for the CHα region are attenuated in the complexes in comparison to spectra of free AD1-ACTR domains presumably due to accelerated transverse relaxation.

Supplementary Fig. 11: Fo-Fc simulated annealing omit map (contoured at 2σ) calculated for ACTR activation domain.

Supplementary Fig. 12: Comparison with the previously reported structures. The X-ray structure of α-methylated [1055meLeu;1076meLeu]AD1-ACTR variant complexed with NCBD of CBP shows similar arrangement of six α-helices with previously solved NMR structure (1KBH) and significant deviations from the other reported structure (6ES7). For comparison, other known structures containing NCBD are superimposed onto new X-ray structure. These include SRC-1 isoform of p160 (2C52), complex with IRF3 (1ZOQ), transactivation domain (TAD) of p53 (2L14), and free NCBD (2KKJ).

Supplementary Fig. 13: Stereochemical Newman projections for residues 1055meLeu (left) and 1076 meLeu (right) in the X-ray structure of [1055meLeu;1076meLeu] AD1-ACTR / NCBD complex. Torsional angles Cγ-Cβ-Cα-Cβ(methyl) are depicted.

Supplementary Fig. 14: The protein-protein interface is less tight than in the NMR complex (1KBH). The overall buried surface area decreased from 1655 to 1066 Å^2. The trend is similar and the highest difference is between residues 1059-1064 (linker between helix 1 and 2), which shows high flexibility in the crystal and the C-terminal helix which no longer makes close interactions with NCBD. Star (*) indicates α-methyl-Leu residues in the sequence.

Supplementary Fig. 15: Visualization of molecular interactions in the crystal. Crystal packing does not affect the orientation of α-helices in the [1055meLeu;1076meLeu]AD1-ACTR / NCBD complex.

Supplementary Fig. 16: Molecular dynamics (MD) simulations of WT AD1-ACTR / NCBD complex and of the corresponding analogues [1055meLeu] and [1055meLeu;1076meLeu]. (a) Backbone atom-positional root-mean-square deviations (RMSD) of complexes from its initial structure indicate a large structural change around 37 ns. The RMSF analysis, Ramachandran plots, hydrogen bonding and salt-bridge analysis therefore exclude the first 50 ns. Black line: WT complex, red line: [1055meLeu]AD1-ACTR/NCBD complex, green line: [1055meLeu;1076meLeu] AD1-ACTR/NCBD complex. (b) Changes in the radii of gyration of the complexes show that the [1055meLeu;1076meLeu]AD1- ACTR/NCBD complex has the most compact structure. (c) The analysis of helical content per residue shows the overall increase of helicity in the ACTR chain that occurs upon α-methylation of Leu1055 and Leu1076. The pre-organization of ACTR analogues into segments with helical conformations was also observed in CD and NMR experiments on free AD1-ACTR proteins. The secondary structural analysis was performed using the DSSP program as implemented in GROMOS[30]. The helical content per residue was calculated as the sum of the occurrences for 3_{10}-helix, α-helix and π-helix. For this analysis the entire trajectory was used. (d) The conformational distribution of the neighboring residues Thr1054, Leu1056, Glu1075 and Val1077 also gets reduced upon α-methylation of Leu1055 and Leu1076. First 50 ns were omitted from the latter analysis.

Supplementary Fig. 17: (a) Overlay of five representative conformations (first five central member structures from the conformational clustering) for MD simulation of wild-type AD1-ACTR/NCBD (left), [1055 meLeu]AD1-ACTR/NCBD (center) and [1055meLeu;1076meLeu]AD1-ACTR/NCBD (right) complexes. In all plots, chain corresponding to ACTR is colored in purple and for NCBD in orange, while residues 1055 and 1076 are highlighted in green. Evident are the structural differences between the complexes and structural variations within each ensemble. Those are the largest for wild type complex and smallest for [1055meLeu]AD1-ACTR/NCBD complex. (b) Comparison of orientation of helices in the structure of wild-type complex determined by NMR (PDB ID: 1KBH), of the [1055meLeu;1076meLeu]AD1-ACTR/NCBD complex determined by X-ray crystallography in this study (PDB ID: 6SQC) and of the first central member structure from the conformational clustering of the corresponding MD simulation.

Supplementary Fig. 18 (consists of 6 panels on pp. 34-38)**:** Surface plasmon resonance binding data for WT AD1-ACTR, [1055meLeu]AD1-ACTR, [1076meLeu]AD1-ACTR and [1055meLeu;1076meLeu] AD1-ACTR at 20 °C (293 K) (curves in black correspond to fitting to 1:1 association model).

Panel 1:

Supplementary Fig. 18: (continued from p. 34) Surface plasmon resonance binding data for WT AD1-ACTR, [1055meLeu]AD1-ACTR, [1076meLeu]AD1-ACTR and [1055meLeu;1076meLeu]AD1-ACTR at 22 °C (295 K) (curves in black correspond to fitting to 1:1 association model).

Panel 2:

Supplementary Fig. 18: (continued from p. 35) Surface plasmon resonance binding data for WT AD1-ACTR, [1055meLeu]AD1-ACTR, [1076meLeu]AD1-ACTR and [1055meLeu;1076meLeu]AD1-ACTR at 25 °C (298 K).

Panel 3:

Supplementary Fig. 18: (continued from p. 36) Surface plasmon resonance binding data for WT AD1-ACTR, [1055meLeu]AD1-ACTR, [1076meLeu]AD1-ACTR and [1055meLeu;1076meLeu]AD1-ACTR at 27 °C (300 K) (curves in black correspond to fitting to 1:1 association model).

Panel 4:

Supplementary Fig. 18: (continued from p. 37) Surface plasmon resonance curves for WT AD1-ACTR, [1055meLeu] AD1-ACTR, [1076meLeu] AD1-ACTR and [1055meLeu;1076meLeu] AD1-ACTR at 31 °C (304 K) (curves in black correspond to fitting to 1:1 association model).

Panel 5:

Supplementary Fig. 19: Steady-state analysis of the NCBD binding to four variants of AD1-ACTR (WT, [1076meLeu], [1055meLeu], [1055meLeu;1076meLeu]) at five different temperatures (a) 20 °C, (b) 22 °C, (c) 25 °C, (d) 27 °C and (e) 31 °C. Normalized equilibrium responses (R_{eq}) plotted as a function of NCBD concentration and fitted with a 1:1 binding model (see Supplementary Table 16 for values of K_D and R_{max}).

Supplementary Fig. 20: Steady-state analysis of the CBP binding to WT AD1-ACTR and [1055meLeu;1076meLeu] variant at 10 °C. Equilibrium responses (R_{eq}) plotted as a function of CBP concentration and fitted using a 1:1 binding model (WT: K_D = 1154 ± 59 nM; [1055meLeu;1076meLeu] AD1-ACTR: K_D = 58 ± 1 nM).

Supplementary Fig. 21: Fluorescent polarization measurements of [1055meLeu;1076meLeu]AD1-ACTR resulted in $K_D = 8.1 \pm 2.5$ nM, whereas for the WT AD1-ACTR K_D could not be calculated accurately because of not reaching the saturation but the affinity is definitively significantly lower. The difference in K_D in the fluorescence polarization and SPR measurements may be explained by differential conditions (FP: T = 25 °C, buffer: 25 mM Hepes pH 7.5, 150 mM NaCl, 1 mM TCEP, 0.05% Tween-20, protease inhibitors versus SPR: T = 10 °C, buffer: 50 mM Tris pH 7.5, 300 mM NaCl, 1 mM TCEP, 0.01% P20, protease inhibitors). In SPR experiments, higher salt concentration was used to minimize nonspecific binding to the chip surface.

Supplementary Fig. 22: SPR binding sensogram of 270 kDa CBP to [1064meLeu;1071meLeu]AD1-ACTR indicating no appreciable binding. Negative signal after subtraction is due to non-specific binding of CBP at higher concentrations.

Supplementary Tables

Supplementary Table 1: Amino acid sequences of the variants of AD1-ACTR studied in this work[#]

	Protein	Sequence
1	wild type (WT) AD1-ACTR	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
2	[S1043M;D1050E;T1054Q]*	EGQMDERALLEQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
3	[A1047G]*	EGQSDERGLLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
4	[1047mA]**	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
5	[1048mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
6	[1049mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
7	[1050mD]**	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
8	[1052mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
9	[1055mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
10	[1056mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
11	[1061mA]**	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
12	[1064mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
13	[1071mL]**	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
14	[1072mA]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
15	[1076mL]**	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
16	[1077mV]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
17	[1080mA]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
18	[1082mA]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
19	[1083mL]**	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
20	[1085mP]**	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
21	[1047mA;1071mL]**	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
22	[1047mA;1072mA]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
23	[1047mA;1076mL]**	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
24	[1047mA;1077mV]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
25	[1047mA;1083mL]**	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
26	[1048mL;1076mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
27	[1048mL;1077mV]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
28	[1048mL;1083mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
29	[1050mD;1071mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
30	[1050mD;1072mA]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
31	[1050mD; 1076mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
32	[1050mD;1077mV]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
33	[1050mD;1083mL]**	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
34	[1055mL;1076mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
35	[1061mA;1071mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
36	[1061mA;1076mL]**	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
37	[1061mA;1077mV]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
38	[1061mA;1083mL]**	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
39	[1064mL;1071mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
40	[1064mL;1076mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
41	[1064mL;1077mV]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
42	[1064mL;1083mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
43	[1047mA;1055mL;1061mA]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
44	[1055mL;1076mL;1083mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
45	[1047mA;1050mD;1061mA;1076mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
46	[1047mA;1055mL;1061mA;1076mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
47	[1047mA;1055mL;1076mL;1083mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
48	[1047mA;1061mA;1076mL;1083mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
49	[1047mA;1055mL;1061mA;1076mL;1083mL]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
50	[1047mA;1055mL;1061mA;1076mL;1083mL;1085mP]	EGQSDERALLDQLHTLLSNTDATGLEEIDRALGIPELVNQGQALEPK
51	NCBD	SALQDLLRTLKSPSSPQQQQQVLNILKSNPQL*Nle*AAFIKQRTAKYVAN***

\# Residues in red are α-methylated;

* These sequences correspond to protein variants with canonical amino acids incorporated to modify the helix propensity: Iešmantavičius et al. *Angew. Chem. Int. Ed.* **2014**, *53*, 1548-1551. We synthesized these protein variants and included them in our study to compare their properties with α-methylated analogues;

** These variants were reported in our previous communication: Schmidtgall et al. *Chem. Commun.* **2017**, *53*, 7369-7372;

*** *Nle* = norleucine in the sequence replaces Met being nearly isosteric to the native residue and resistant to oxidation.

Supplementary Table 2: Characterization of synthesized proteins by mass-spectrometry**

Protein	Measured mass [Da]	Calculated mass [Da]
[S1043M;D1050E;T1054Q]	5184.9	5184.8
[A1047G]	5085.1	5085.6
[1048mL]	5113.7	5113.6
[1049mL]	5113.6	5113.6
[1052mL]	5113.6	5113.6
[1055mL]	5113.6	5113.6
[1056mL]	5113.6	5113.6
[1064mL]	5112.6	5113.6
[1072mA]	5128.3	5127.6
[1077mV]	5114.6	5113.6
[1080mA]	5127.9	5127.6
[1082mA]	5113.8	5113.6
[1047mA;1072mA]	5142.2	5141.6
[1047mA;1077mV]	5128.0	5127.6
[1048mL;1076mL]	5127.6	5127.6
[1048mL;1077mV]	5127.6	5127.6
[1048mL;1083mL]	5127.6	5127.6
[1050mD;1071mL]	5127.5	5127.6
[1050mD;1072mA]	5141.4	5141.6
[1050mD; 1076mL]	5127.5	5127.6
[1050mD;1077mV]	5126.6	5127.6
[1055mL;1076mL]	5127.6	5127.6
[1061mA;1071mL]	5128.8	5127.6
[1061mA;1077mV]	5127.9	5127.6
[1064mL;1071mL]	5127.6	5127.6
[1064mL;1076mL]	5127.1	5127.6
[1064mL;1077mV]	5127.9	5127.6
[1064mL;1083mL]	5128.3	5127.6
[1047mA;1055mL;1061mA]	5141.6	5141.6
[1055mL;1076mL;1083mL]	5141.0	5141.6
[1047mA;1050mD;1061mA;1076mL]	5155.7	5155.7
[1047mA;1055mL;1061mA;1076mL]	5155.0	5155.7
[1047mA;1055mL;1076mL;1083mL]	5155.7	5155.7
[1047mA;1061mA;1076mL;1083mL]	5155.5	5155.7
[1047mA;1055mL;1061mA;1076mL;1083mL]	5169.7	5169.7
[1047mA;1055mL;1061mA;1076mL;1083mL;1085mP]	5183.7	5183.7
WT-AD1-ACTR-GGG-(PEG)$_3$-K(Biotin)-amide*	5826.5	5827.5
[1055mL]AD1-ACTR-GGG-(PEG)$_3$-K(Biotin)-amide*	5841.3	5841.5
[1076mL]AD1-ACTR-GGG-(PEG)$_3$-K(Biotin)-amide*	5841.7	5841.5
[1055mL;1076mL]AD1-ACTR-GGG-(PEG)$_3$-K(Biotin)-amide*	5854.9	5855.5
[1064mL;1071mL]AD1-ACTR-GGG-(PEG)$_3$-K(Biotin)-amide*	5854.2	5855.5
Fluo-(PEG)$_5$-WT-AD1-ACTR*	5879.3	5880.5
Fluo-(PEG)$_5$-[1055meLeu;1076meLeu]-AD1-ACTR*	5907.3	5908.5

* The exact chemical structures for '(PEG)$_3$' and 'Fluo-(PEG)$_5$' are provided on p.3 of Supplementary Materials and Methods;

** Analytical characterization of the variants marked with two asterisks (**) in Table 1 is not listed here and reported in our previous communication: Schmidtgall et al. *Chem. Commun.* **2017**, *53*, 7369-7372.

Supplementary Table 3: Thermodynamic parameters of binding of AD1-ACTR variants to NCBD obtained by isothermal titration calorimetry (ITC)*

	Protein	K_d [µM]	ΔG [kcal mol^{-1}]	ΔH [kcal mol^{-1}]	$-T\Delta S$ [kcal mol^{-1}]
1	wild type (WT) AD1-ACTR**	0.206	-9.30	-12.7	3.40
2	[S1043M;D1050E;T1054Q]	0.188	-9.36	-13.7	4.29
3	[A1047G]	0.844	-8.45	-13.8	5.33
4	[1047mA]**	0.145	-9.51	-11.8	2.29
5	[1048mL]	0.281	-9.12	-12.2	3.04
6	[1049mL]	0.806	-8.48	-14.8	6.32
7	[1050mD]**	0.800	-8.48	-11.7	3.22
8	[1052mL]	0.634	-8.63	-12.1	3.52
9	[1055mL]	0.075	-9.91	-18.7	8.78
10	[1056mL]	2.60	-7.77	-9.07	1.30
11	[1061mA]**	0.327	-9.02	-13.6	4.58
12	[1064mL]	1.34	-8.17	-12.6	4.43
13	[1071mL]**	7.11	-7.16	-5.58	-1.58
14	[1072mA]	0.144	-9.52	-11.8	2.30
15	[1076mL]**	0.206	-9.30	-15.0	5.70
16	[1077mV]	0.347	-8.99	-20.5	11.5
17	[1080mA]	0.496	-8.77	-19.4	10.7
18	[1082mA]	0.518	-8.75	-18.3	9.58
19	[1083mL]**	0.520	-8.74	-13.1	4.36
20	[1085mP]**	0.487	-8.78	-14.8	6.02
21	[1047mA;1071mL]**	5.11	-7.36	-5.18	-2.18
22	[1047mA;1072mA]	0.569	-8.69	-15.2	6.51
23	[1047mA;1076mL]**	0.055	-10.1	-13.2	3.10
24	[1047mA;1077mV]	0.311	-9.06	-18.9	9.88
25	[1047mA;1083mL]**	0.166	-9.43	-11.5	2.07
26	[1048mL;1076mL]	0.301	-9.08	-15.9	6.79
27	[1048mL;1077mV]	0.483	-8.79	-14.4	5.59
28	[1048mL;1083mL]	0.788	-8.49	-13.4	4.97
29	[1050mD; 1071mL]	4.99	-7.37	-4.20	-3.18
30	[1050mD;1072mA]	0.798	-8.49	-14.3	5.86
31	[1050mD; 1076mL]	0.659	-8.60	-17.1	8.46
32	[1050mD;1077mV]	0.595	-8.66	-16.5	7.81
33	[1050mD;1083mL]**	0.614	-8.64	-11.7	3.06
34	[1055mL;1076mL]	0.042	-10.3	-20.4	10.1
35	[1061mA;1071mL]	3.37	-7.62	-6.50	-1.12
36	[1061mA;1076mL]**	0.180	-9.38	-16.3	6.92
37	[1061mA;1077mV]	0.236	-9.22	-19.2	9.96
38	[1061mA;1083mL]**	0.277	-9.12	-15.3	6.18
39	[1064mL;1071mL]	6.05	-7.26	-2.20	-5.06
40	[1064mL;1076mL]	0.796	-8.49	-15.4	6.94
41	[1064mL;1077mV]	0.829	-8.46	-15.2	6.69
42	[1064mL;1083mL]	1.60	-8.07	-13.3	5.20
43	[1047mA;1055mL;1061mA]	0.177	-9.40	-20.2	10.8
44	[1055mL;1076mL;1083mL]	0.042	-10.3	-20.3	10.0
45	[1047mA;1050mD;1061mA;1076mL]	0.221	-9.20	-18.1	8.91
46	[1047mA;1055mL;1061mA;1076mL]	0.136	-9.56	-21.6	12.0
47	[1047mA;1055mL;1076mL;1083mL]	0.298	-9.07	-16.8	7.71
48	[1047mA;1061mA;1076mL;1083mL]	0.155	-9.48	-18.6	9.16
49	[1047mA;1055mL;1061mA;1076mL;1083mL]	0.090	-9.80	-21.8	12.0
50	[1047mA;1055mL;1061mA;1076mL;1083mL; 1085mP]	0.108	-9.70	-20.5	10.8

* The ITC data for 13 analogues marked with two asterisks (**) was published in our previous communication: Schmidtgall et al. *Chem. Commun.* **2017**, *53*, 7369-7372.

Supplementary Table 4: Apparent melting points of AD1-ACTR/NCBD complexes (CD-monitored)

AD1-ACTR variant complexed with NCBD	T_m [°C]
WT	69
[1071mL]	50
[1047mA;1071mL]	50
[A1047G]	67
[1050mD]	67
[1056mL]	66
[1047mA;1076mL]	73
[S1043M;D1050E;T1054Q]	74
[1055mL]	>85
[1055mL;1076mL]	>85
[1047mA;1061mA;1076mL;1083mL]	>85
[1047mA;1055mL;1061mA;1076mL;1083mL]	>85
[1047mA;1055mL;1061mA;1076mL;1083mL;1086mP]	>85

Supplementary Table 5: Ratios of ellipticities in CD spectra of AD1-ACTR variants

	Protein	$\theta_{222}/\theta_{199}$
1	WT AD1-ACTR	0.23
2	[S1043M;D1050E;T1054Q]	0.33
3	[A1047G]	0.20
4	[1047mA]**	0.23
5	[1048mL]	0.30
6	[1049mL]	0.28
7	[1050mD]**	0.26
8	[1052mL]	0.31
9	[1055mL]	0.44
10	[1056mL]	0.26
11	[1061mA]**	0.24
12	[1064mL]	0.25
13	[1071mL]**	0.24
14	[1072mA]	0.26
15	[1076mL]**	0.27
16	[1077mV]	0.29
17	[1080mA]	0.24
18	[1082mA]	0.25
19	[1083mL]**	0.26
20	[1085mP]**	0.25
21	[1047mA;1071mL]**	0.26
22	[1047mA;1072mA]	0.24
23	[1047mA;1076mL]**	0.28
24	[1047mA;1077mV]	0.29
25	[1047mA;1083mL]**	0.25
26	[1048mL;1076mL]	0.34
27	[1048mL;1077mV]	0.37
28	[1048mL;1083mL]	0.28
29	[1050mD; 1071mL]	0.21
30	[1050mD;1072mA]	0.23
31	[1050mD; 1076mL]	0.23
32	[1050mD;1077mV]	0.24
33	[1050mD;1083mL]**	0.27
34	[1055mL;1076mL]	0.40
35	[1061mA;1071mL]	0.25
36	[1061mA;1076mL]**	0.31
37	[1061mA;1077mV]	0.30
38	[1061mA;1083mL]**	0.25
39	[1064mL;1071mL]	0.26
40	[1064mL;1076mL]	0.28
41	[1064mL;1077mV]	0.33
42	[1064mL;1083mL]	0.23
43	[1047mA;1055mL;1061mA]	0.48
44	[1055mL;1076mL;1083mL]	0.50
45	[1047mA;1050mD;1061mA;1076mL]	0.29
46	[1047mA;1055mL;1061mA; 1076mL]	0.57
47	[1047mA;1055mL;1076mL;1083mL]	0.63
48	[1047mA;1061mA;1076mL;1083mL]	0.29
49	[1047mA;1055mL;1061mA;1076mL;1083mL]	0.61
50	[1047mA;1055mL;1061mA;1076mL;1083mL;1085mP]	0.75

** The CD spectra for these analogues were previously published in our preceding communication: Schmidtgall et al. *Chem. Commun.* **2017**, *53*, 7369-7372.

Supplementary Table 6: Ratios of ellipticities in CD spectra of AD1-ACTR variants complexes with NCBD

	Protein complex	$\theta_{222}/\theta_{208}$
1	WT AD1-ACTR / NCBD	0.949
2	[S1043M;D1050E;T1054Q] / NCBD	0.948
3	[A1047G] / NCBD	0.924
4	[1047mA] / NCBD**	0.964
5	[1048mL] / NCBD	0.953
6	[1049mL] / NCBD	0.944
7	[1050mD] / NCBD**	0.934
8	[1052mL] / NCBD	0.941
9	[1055mL] / NCBD	0.960
10	[1056mL] / NCBD	0.922
11	[1061mA] / NCBD**	0.949
12	[1064mL] / NCBD	0.935
13	[1071mL] / NCBD**	0.889
14	[1072mA] / NCBD	0.939
15	[1076mL] / NCBD**	1.00
16	[1077mV] / NCBD	0.932
17	[1080mA] / NCBD	0.968
18	[1082mA] / NCBD	0.963
19	[1083mL] / NCBD**	0.968
20	[1085mP] / NCBD**	0.975
21	[1047mA;1071mL] / NCBD**	0.893
22	[1047mA;1072mA] / NCBD	0.959
23	[1047mA;1076mL] / NCBD**	1.02
24	[1047mA;1077mV] / NCBD	0.987
25	[1047mA;1083mL] / NCBD**	0.924
26	[1048mL;1076mL] / NCBD	0.974
27	[1048mL;1077mV] / NCBD	0.977
28	[1048mL;1083mL] / NCBD	0.943
29	[1050mD; 1071mL] / NCBD	0.944
30	[1050mD;1072mA] / NCBD	0.943
31	[1050mD; 1076mL] / NCBD	0.979
32	[1050mD;1077mV] / NCBD	0.981
33	[1050mD;1083mL] / NCBD**	0.980
34	[1055mL;1076mL] / NCBD	0.949
35	[1061mA;1071mL] / NCBD	0.900
36	[1061mA;1076mL] / NCBD**	0.989
37	[1061mA;1077mV] / NCBD	0.993
38	[1061mA;1083mL] / NCBD**	0.981
39	[1064mL;1071mL] / NCBD	0.882
40	[1064mL;1076mL] / NCBD	0.973
41	[1064mL;1077mV] / NCBD	0.953
42	[1064mL;1083mL] / NCBD	0.938
43	[1047mA;1055mL;1061mA] / NCBD	0.973
44	[1055mL;1076mL;1083mL] / NCBD	1.02
45	[1047mA;1050mD;1061mA;1076mL] / NCBD	1.01
46	[1047mA;1055mL;1061mA; 1076mL] / NCBD	0.996
47	[1047mA;1055mL;1076mL;1083mL] / NCBD	0.965
48	[1047mA;1061mA;1076mL;1083mL] / NCBD	0.986
49	[1047mA;1055mL;1061mA;1076mL;1083mL] / NCBD	0.990
50	[1047mA;1055mL;1061mA;1076mL;1083mL;1085mP] / NCBD	0.994

** The CD spectra for these analogues were previously published in our preceding communication:
Schmidtgall et al. *Chem. Commun.* **2017**, *53*, 7369-7372.

Supplementary Table 7: Chemical shifts (ppm) for wild type [1040-1086]-fragment of AD1-ACTR measured on a 700 MHz spectrometer used to calculate secondary chemical shifts

Residue number	Residue type	Hα	Cα	Cβ
1040	E	not determined	not determined	not determined
1041	G	4.008	45.136	not present
1042	Q	4.415	55.818	29.566
1043	S	4.441	58.257	63.699
1044	D	4.611	54.425	41.175
1045	E	4.188	57.569	29.878
1046	R	4.205	56.889	30.325
1047	A	4.249	53.193	18.778
1048	L	4.262	55.807	not assigned
1049	L	4.230	56.089	not assigned
1050	D	4.537	55.082	40.978
1051	Q	4.275	56.359	29.160
1052	L	4.251	55.927	not assigned
1053	H	4.573	57.182	30.926
1054	T	4.227	62.600	69.496
1055	L	4.363	55.206	not assigned
1056	L	4.363	55.240	not assigned
1057	S	4.447	58.437	63.746
1058	N	4.803	53.316	38.898
1059	T	4.341	61.985	69.592
1060	D	4.615	54.391	41.134
1061	A	4.381	52.635	19.113
1062	T	4.295	62.508	69.849
1063	G	3.980	45.452	not present
1064	L	4.340	54.830	not assigned
1065	E	4.244	57.036	30.158
1066	E	4.264	56.773	30.150
1067	I	4.100	61.515	38.933
1068	D	4.563	54.650	41.001
1069	R	4.233	56.581	30.527
1070	A	4.274	52.797	18.824
1071	L	4.300	55.270	not assigned
1072	G	3.880	45.108	not present
1073	I	4.443	58.970	38.389
1074	P	4.374	63.692	32.081
1075	E	4.211	56.942	30.196
1076	L	4.344	55.247	not assigned
1077	V	4.077	62.512	32.748
1078	N	4.692	53.267	38.769
1079	Q	4.305	56.228	29.229
1080	G	3.944	45.391	not present
1081	Q	4.324	55.657	29.646
1082	A	4.313	52.366	19.063
1083	L	4.336	55.593	not assigned
1084	E	4.580	54.229	29.933
1085	P	4.413	63.335	31.919
1086	K	4.169	57.434	33.957

Supplementary Table 8: Chemical shifts (ppm) for [1055meLeu] variant of [1040-1086]-fragment of AD1-ACTR measured on a 700 MHz spectrometer used to calculate secondary chemical shifts

Residue number	Residue type	Hα	Cα	Cβ
1040	E	not determined	not determined	not determined
1041	G	4.042	45.134	not present
1042	Q	4.408	55.897	29.548
1043	S	4.442	58.500	63.6830
1044	D	4.609	54.442	41.172
1045	E	4.165	57.827	29.870
1046	R	4.181	57.143	30.2490
1047	A	4.245	53.484	18.660
1048	L	4.225	56.209	not assigned
1049	L	4.195	56.332	not assigned
1050	D	4.524	55.631	40.899
1051	Q	4.181	56.383	28.904
1052	L	4.186	56.372	not assigned
1053	H	4.483	58.010	30.642
1054	T	4.062	64.236	69.290
1055	mL (meLeu)	n/a	n/a	α-CH$_3$ (C: 23.79 ppm; H 1.501 ppm), Leu side chain not assigned
1056	L	4.195	56.391	not assigned
1057	S	4.381	59.288	63.586
1058	N	4.834	53.341	39.066
1059	T	4.359	62.149	69.749
1060	D	4.617	54.388	41.116
1061	A	4.368	52.709	19.131
1062	T	4.283	62.625	69.805
1063	G	3.979	45.498	not present
1064	L	4.400	54.823	not assigned
1065	E	4.229	57.167	30.144
1066	E	4.257	56.834	30.096
1067	I	4.085	61.599	38.890
1068	D	4.552	54.748	41.000
1069	R	4.224	56.624	30.508
1070	A	4.269	52.845	18.843
1071	L	4.296	55.278	not assigned
1072	G	3.868	45.112	not present
1073	I	4.432	59.036	38.355
1074	P	4.369	63.746	32.068
1075	E	4.205	57.003	30.185
1076	L	4.355	55.258	not assigned
1077	V	4.072	62.530	32.741
1078	N	4.690	53.280	38.716
1079	Q	4.302	56.257	29.222
1080	G	3.943	45.396	not present
1081	Q	4.322	55.679	29.633
1082	A	4.311	52.376	19.078
1083	L	4.333	55.298	not assigned
1084	E	4.578	54.238	29.933
1085	P	4.412	63.325	31.925
1086	K	4.167	57.419	33.957

Supplementary Table 9: Chemical shifts (ppm) for [1055meLeu;1076meLeu] variant of [1040-1086]-fragment of AD1-ACTR measured on a 700 MHz spectrometer used to calculate secondary chemical shifts

Residue number	Residue type	Hα	Cα	Cβ
1040	E	not determined	not determined	not determined
1041	G	4.029	45.138	not present
1042	Q	4.414	55.848	29.561
1043	S	4.445	58.469	63.703
1044	D	4.612	54.437	41.158
1045	E	4.164	57.857	29.856
1046	R	4.178	57.160	30.239
1047	A	4.244	53.514	18.641
1048	L	4.223	56.303	not assigned
1049	L	4.184	56.433	not assigned
1050	D	4.522	55.732	40.867
1051	Q	4.173	56.432	28.905
1052	L	4.181	56.434	not assigned
1053	H	4.466	58.159	30.675
1054	T	4.045	64.419	69.241
1055	mL (meLeu)	n/a	n/a	α-CH$_3$ (C: 23.68 ppm; H: 1.500 pm), Leu side chain not assigned
1056	L	4.177	56.436	not assigned
1057	S	4.380	59.356	63.580
1058	N	4.838	53.321	39.102
1059	T	4.361	62.150	69.740
1060	D	4.619	54.381	41.114
1061	A	4.362	52.768	19.112
1062	T	4.280	62.671	69.787
1063	G	3.978	45.503	not present
1064	L	4.334	54.843	not assigned
1065	E	4.224	57.241	30.110
1066	E	4.253	56.884	30.111
1067	I	4.077	61.677	38.868
1068	D	4.548	54.802	41.018
1069	R	4.217	56.689	30.498
1070	A	4.269	52.905	18.831
1071	L	4.300	55.302	not assigned
1072	G	3.880	45.149	not present
1073	I	4.408	59.205	38.289
1074	P	4.397	63.589	32.083
1075	E	4.133	57.820	29.891
1076	mL (meLeu)	n/a	n/a	α-CH$_3$ (C: 24.54 ppm; H: 1.444 ppm), Leu side chain not assigned
1077	V	3.928	63.806	32.180
1078	N	4.704	53.641	38.847
1079	Q	4.307	56.411	29.133
1080	G	3.956	45.506	not present
1081	Q	4.327	55.685	29.600
1082	A	4.315	52.357	19.093
1083	L	4.329	55.363	not assigned
1084	E	4.578	54.226	29.935
1085	P	4.411	63.330	31.929
1086	K	4.169	57.430	33.962

Supplementary Table 10: The $^{13}C\alpha$ spin-lattice R_1 relaxation rates (s^{-1}) for wild type AD1-ACTR, [1055meLeu] and [1055meLeu;1076meLeu] variants

Residue	WT AD1-ACTR		[1055meLeu]		[1055meLeu;1076meLeu]	
	R_1	uncertainty	R_1	uncertainty	R_1	uncertainty
1040	N/A	N/A	N/A	N/A	N/A	N/A
1041	N/A	N/A	N/A	N/A	N/A	N/A
1042	2.29	1.15	2.40	1.56	2.53	1.15
1043	2.22	0.832	2.23	0.647	2.44	1.44
1044	2.38	0.882	2.30	0.836	2.49	1.80
1045	2.50	1.41	2.11	0.864	1.96	1.02
1046	2.49	1.76	2.56	1.36	2.17	1.01
1047	2.35	0.772	2.27	0.579	2.42	1.27
1048	2.55	0.870	1.65	0.405	1.90	0.80
1049	2.47	1.04	2.40	0.953	2.17	1.29
1050	2.25	0.839	2.45	1.43	2.44	1.45
1051	2.48	0.887	1.94	1.21	2.37	1.49
1052	2.26	1.13	2.37	0.507	2.00	1.17
1053	2.31	0.579	2.22	1.15	2.71	0.853
1054	2.36	0.777	2.41	1.05	2.50	1.47
1055	2.26	1.61	N/A	N/A	N/A	N/A
1056	2.40	1.59	2.40	0.953	2.10	1.04
1057	2.32	1.16	2.21	1.06	2.18	1.23
1058	2.33	0.871	2.18	1.06	2.28	1.60
1059	2.41	1.12	2.12	1.46	2.53	1.40
1060	2.46	0.842	2.32	1.04	2.30	1.21
1061	2.14	1.01	2.29	0.894	2.18	1.14
1062	2.25	1.04	2.08	0.875	2.14	1.57
1063	N/A	N/A	N/A	N/A	N/A	N/A
1064	2.51	1.08	2.38	0.880	2.71	1.13
1065	2.46	0.762	2.25	0.488	2.24	1.13
1066	2.37	1.51	2.43	0.624	2.42	1.03
1067	2.40	1.48	2.11	0.787	2.24	0.947
1068	2.36	1.45	2.31	1.09	2.64	0.569
1069	2.31	0.881	2.22	0.743	2.54	0.995
1070	2.35	0.893	2.00	1.19	2.02	1.14
1071	2.41	0.628	2.26	0.894	1.89	0.713
1072	N/A	N/A	N/A	N/A	N/A	N/A
1073	2.61	0.858	2.45	1.28	2.36	1.21
1074	2.45	0.703	2.37	0.683	2.30	1.01
1075	2.37	1.37	2.00	0.837	2.54	0.988
1076	2.39	1.02	2.20	0.789	N/A	N/A
1077	2.50	1.05	2.50	1.11	2.36	1.05
1078	2.67	1.10	2.51	0.875	2.25	2.22
1079	2.23	1.15	2.15	0.842	2.37	0.789
1080	N/A	N/A	N/A	N/A	N/A	N/A
1081	2.45	1.16	2.45	0.768	2.55	0.615
1082	2.33	1.10	2.50	1.17	2.07	1.10
1083	2.54	1.02	2.44	0.887	2.10	0.832
1084	2.58	0.988	2.63	0.973	2.61	0.784
1085	2.37	1.63	2.38	0.476	2.25	0.704
1086	1.97	0.971	1.96	1.02	1.86	1.28

Supplementary Table 11: The $^{13}C\alpha$ spin-spin R_2 relaxation rates (s^{-1}) for wild type AD1-ACTR, [1055meLeu] and [1055meLeu;1076meLeu] variants

Residue	WT AD1-ACTR		[1055meLeu]		[1055meLeu;1076meLeu]	
	R_2	uncertainty	R_2	uncertainty	R_2	uncertainty
1040	N/A	N/A	N/A	N/A	N/A	N/A
1041	N/A	N/A	N/A	N/A	N/A	N/A
1042	3.25	1.04	3.92	0.937	4.09	0.708
1043	4.33	0.694	4.43	1.29	5.48	1.11
1044	5.28	1.10	5.56	1.27	5.98	1.31
1045	5.76	0.864	6.67	1.10	8.66	0.923
1046	5.66	0.772	8.78	1.18	6.48	0.451
1047	5.49	1.39	8.21	0.871	8.61	0.701
1048	5.23	0.805	7.31	0.932	11.0	0.984
1049	6.24	1.16	8.66	0.668	10.5	0.515
1050	6.00	0.405	13.2	1.36	16.0	0.853
1051	6.87	0.970	9.44	1.17	9.45	1.27
1052	6.58	1.45	11.0	0.958	10.2	1.01
1053	6.85	0.744	10.6	0.967	14.3	0.801
1054	6.14	0.834	14.0	0.831	24.9	0.689
1055	5.17	0.615	N/A	N/A	N/A	N/A
1056	6.31	0.917	8.66	0.668	9.73	1.17
1057	4.37	1.12	9.41	0.507	9.83	1.26
1058	5.10	0.745	6.70	0.671	7.23	0.748
1059	5.39	0.990	5.99	1.20	7.45	1.05
1060	4.87	0.598	5.48	0.922	5.62	1.35
1061	4.75	0.696	4.50	1.20	6.55	1.16
1062	4.70	0.844	5.59	1.30	6.89	1.01
1063	N/A	N/A	N/A	N/A	N/A	N/A
1064	4.18	0.900	4.10	1.07	4.45	0.672
1065	6.20	1.01	9.62	1.02	10.5	0.976
1066	7.51	1.25	7.02	1.15	8.00	0.974
1067	6.59	0.843	6.92	0.380	9.04	0.999
1068	6.28	1.46	7.90	0.520	8.18	0.926
1069	5.58	0.920	8.06	1.43	8.71	0.649
1070	5.21	0.710	7.00	1.22	6.70	0.791
1071	5.37	0.968	5.51	1.52	5.46	0.880
1072	N/A	N/A	N/A	N/A	N/A	N/A
1073	8.42	0.860	7.77	0.999	13.0	0.524
1074	5.64	0.396	6.73	1.05	8.32	0.842
1075	6.98	0.868	6.58	1.05	8.06	0.549
1076	6.01	0.802	6.15	1.57	N/A	N/A
1077	4.54	0.439	4.74	0.835	7.28	1.08
1078	4.67	1.22	5.26	0.795	6.50	0.965
1079	4.87	0.716	5.48	0.918	6.02	1.12
1080	N/A	N/A	N/A	N/A	N/A	N/A
1081	4.59	0.900	4.18	0.888	4.90	1.43
1082	3.50	1.14	3.26	0.775	4.24	0.729
1083	5.32	0.637	5.51	1.016	7.31	1.11
1084	3.91	0.687	4.05	0.828	4.00	0.579
1085	2.83	1.08	3.12	1.01	3.10	0.574
1086	2.55	0.853	2.73	0.557	2.76	1.069

Supplementary Table 12: Crystallographic data collection and refinement statistics for the complex of NCBD with [1055meLeu;1076meLeu]AD1-ACTR variant (values in parentheses are for the highest resolution shell)

Data collection	
X-ray source	Swiss Light Source (PXIII beamline)
Wavelength	1.00003 Å
Resolution range	41.72 - 2.28 Å (2.362 - 2.28 Å)
Space group	*C* 2
Unit cell	*a* = 103.18 Å, *b* = 42.46 Å, *c* = 113.79 Å, α = γ = 90°, β = 101.125°
Total reflections	73662 (7372)
Unique reflections	21924 (2175)
Multiplicity	3.4 (3.4)
Completeness	97.23 % (96.97 %)
Mean I/sigma(I)	9.58 (1.94)
Wilson B-factor	33.76 Å^2
R-merge	0.09578 (0.6837)
CC1/2	0.995 (0.745)
Refinement	
Reflections used in refinement	21873 (2173)
Reflections used for R-free	1100 (107)
R-work	0.2264 (0.2965)
R-free	0.2712 (0.3260)
Number of non-hydrogen atoms	3765
macromolecules	3578
ligands	29
solvent	158
Protein residues	466
RMS(bonds)	0.006
RMS(angles)	1.13
Ramachandran favored	97.36 %
Ramachandran allowed	2.64 %
Ramachandran outliers	0 %
Rotamer outliers	2.72 %
Clash score	7.93
Average B-factor	50.92 Å^2
macromolecules	51.33 Å^2
ligands	36.86 Å^2
solvent	44.35 Å^2
Number of TLS groups	8

Supplementary Table 13: Hydrogen bond analysis. The increase in occurrences of intermolecular hydrogen bonds between AD1-ACTR and NCBD for the [1055meLeu]AD1-ACTR and [1055meLeu;1076meLeu]AD1-ACTR analogues indicates the increase in stabilizing interactions between the two proteins and agrees with enhanced binding affinities observed for NCBD binding. The differences in the hydrogen bonding patterns between activation domain of ACTR and NCBD for different complexes indicate structural differences between the three complexes. Listed are hydrogen bonds that occur for at least 20% of the time in at least one of the three complexes. Shaded in gray are hydrogen bonds that occur in at least two complexes (10 out of 40). First 50 ns were excluded from the analysis.

Hydrogen Bond	Occurrence (%)		
	WT AD1-ACTR / NCBD	[1055mL] AD1-ACTR / NCBD	[1055mL;1076mL] AD1-ACTR / NCBD
ACTR:Glu1066 NH – NCBD:Ser2077 O	0.0	69.7	0.0
NCBD:Ser2077 NH – ACTR:Leu1064 O	0.0	65.9	0.0
NCBD:Gln2086 NH – ACTR:Glu1065 OE1	0.0	65.5	0.0
NCBD:Gln2085 NE2HE22 – ACTR:Glu1065 OE2	0.0	63.6	0.0
NCBD:Lys2076 NH - ACTR:Gly1063 O	0.0	60.8	0.0
NCBD:Leu2088 NH – ACTR:Glu1065 OE2	0.0	58.3	0.0
NCBD:Val2087 NH – ACTR:Glu1065 OE2	0.0	55.3	0.0
NCBD:Ser2079 NH – ACTR:Glu1065 OE2	13.9	0.0	49.9
NCBD:Gln2104 NH – ACTR:Asp1068 OD1	0.0	0.0	48.9
NCBD:Ser2079 NH – ACTR:Glu1065 OE1	10.8	0.0	48.4
NCBD:Ser2079 OGHG – ACTR:Glu1065 OE1	5.1	4.6	44.6
NCBD:Ser2079 OGHG – ACTR:Glu1065 OE2	2.5	3.1	44.4
NCBD:Lys2103 NH – ACTR:Asp1068 OD1	0.0	0.0	43.7
NCBD:Val2087 NH – ACTR:Glu1065 OE1	0.0	43.6	0.0
NCBD:Gln2085 NE2HE21 – ACTR:Glu1066 O	0.0	41.6	0.0
NCBD:Gln2085 NE2HE22 – ACTR:Glu1065 OE1	0.0	39.7	0.0
NCBD:Gln2104 NH – ACTR:Asp1068 OD2	0.0	0.0	38.8
NCBD:Ser2080 NH - ACTR:Glu1065 OE2	38.2	3.2	19.1
NCBD:Lys2103 NH – ACTR:Asp1068 OD2	0.0	0.0	36.1
NCBD:Ser2080 OGHG - ACTR:Glu1065 OE2	36.1	1.5	16.9
NCBD:Gln2086 NE2HE22 – ACTR:Glu1065 OE1	0.0	35.4	0.0
NCBD:Arg2105 NH - ACTR:Asp1068 OD1	0.0	0.0	34.9
NCBD:Arg2105 NH - ACTR:Asp1068 OD2	0.0	0.0	34.9
ACTR:Leu1064 NH – NCBD:Leu2091 O	34.4	0.0	0.0
NCBD:Ser2079 NH – ACTR:Glu1066 OE2	0.0	34.2	0.0
ACTR:Leu25 NH – NCBD:Leu2075 O	0.0	0.0	33.7
NCBD:Ser2080 NH – ACTR:Glu1065 OE1	33.5	19.7	15.1
NCBD:Arg2105 NEHE – ACTR:Asp1068 O	0.0	0.0	32.9
ACTR:Gly24 NH – NCBD:Leu2075 O	0.0	0.0	31.4
NCBD:Ser2080 OGHG – ACTR:Glu1065 OE1	29.4	2.0	15.5
NCBD:Ser2079 NH – ACTR:Glu1066 OE1	0.0	29.3	0.0
NCBD:Asn2089 ND2HD22 – ACTR:Thr1054 O	28.0	0.0	0.0
NCBD:Ser2079 OGHG – ACTR:Glu1066 OE2	0.0	24.5	0.0
NCBD:Gln2086 NH – ACTR:Glu1065 OE2	0.0	24.2	0.0
NCBD:Leu2068 NH – ACTR:Asn1058 O	21.9	0.0	0.0
NCBD:Ser2079 OGHG – ACTR:Glu1066 OE1	0.0	21.9	0.0
NCBD:Thr2106 OG1HG1 - ACTR:Glu1084 OE2	21.6	0.0	0.0
NCBD:Tyr2109 OHHH – ACTR:Asp1068 OD2	0.0	20.6	1.2
NCBD:Tyr2109 OHHH – ACTR:Asp1068 OD1	0.0	20.2	3.2
NCBD:Thr2106 NH – ACTR:Glu1084 OE2	20.0	0.0	0.0

Supplementary Table 14: Salt-bridge analysis. The differences in occurrences of intermolecular and intramolecular salt bridges between AD1-ACTR and NCBD for the three complexes agree with the results of the hydrogen bond analysis and indicate structural differences at the ACTR/NCBD interface of the complexes. First 50 ns are excluded from the analysis.

Intermolecular salt bridges:

Salt Bridge	Occurrence (%)		
	WT AD1-ACTR / NCBD	[1055mL] AD1-ACTR / NCBD	[1055mL;1076mL] AD1-ACTR / NCBD
ACTR:Glu1045 OE1 – NCBD:Arg2073 NH2	30.9	7.2	0.2
ACTR:Glu1045 OE2 – NCBD:Arg2073 NH2	30.6	7.5	0.2
ACTR:Asp1060 OD2 – NCBD:Lys2092 NZ	24.3	0.0	0.0
ACTR:Glu1045 OE1 – NCBD:Arg2073 NH1	23.1	3.8	0.2
ACTR:Asp1060 OD1 – NCBD:Lys2092 NZ	23.1	0.0	0.0
ACTR:Glu1045 OE2 – NCBD:Arg2073 NH1	22.0	3.9	0.2
ACTR:Glu1066 OE1 – NCBD:Lys2076 NZ	13.7	8.9	0.0
ACTR:Glu1066 OE2 – NCBD:Lys2076 NZ	12.5	8.8	0.0
ACTR:Glu1084 OE1 – NCBD:Lys2108 NZ	10.7	0.0	0.0
ACTR:Asp1060 OD1 – NCBD:Arg2105 NH2	0.0	29.5	0.0
ACTR:Asp1060 OD2 – NCBD:Arg2105 NH2	0.0	29.2	0.0
ACTR:Asp1060 OD1 – NCBD:Arg2105 NH1	0.0	12.5	0.0
ACTR:Asp1060 OD2 – NCBD:Arg2105 NH1	0.0	13.0	0.0
ACTR:Asp1068 OD1 – NCBD:Arg2105 NH2	1.6	27.3	14.5
ACTR:Asp1068 OD2 – NCBD:Arg2105 NH2	1.8	26.9	15.5
ACTR:Asp1068 OD1 – NCBD:Arg2105 NH1	1.3	21.5	12.8
ACTR:Asp1068 OD2 – NCBD:Arg2105 NH1	1.3	20.7	12.8
ACTR:Asp1060 OD1 – NCBD:Lys2076 NZ	0.0	1.5	29.9
ACTR:Asp1060 OD2 – NCBD:Lys2076 NZ	0.0	1.3	29.5
ACTR:Glu1075 OE2 – NCBD:Lys2092 NZ	0.0	1.8	23.1
ACTR:Glu1075 OE1 – NCBD:Lys2092 NZ	0.0	1.6	21.7
ACTR:Glu1066 OE1 – NCBD:Lys2103 NZ	6.2	0.0	12.3
ACTR:Glu1066 OE2 – NCBD:Lys2103 NZ	6.7	0.0	11.9

Intramolecular salt bridges:

Salt Bridge	Occurrence (%)		
	WT AD1-ACTR / NCBD	[1055mL] AD1-ACTR / NCBD	[1055mL;1076mL] AD1-ACTR / NCBD
ASP1050 OD2 - HIS1053 NE2	19.4	27.3	3.0
ASP1050 OD1 - HIS1053 NE2	18.7	29.7	3.0
Glu1084 OE2 – LYS1086 NZ	16.7	28.3	19.8
Glu1084 OE1 – LYS1086 NZ	15.6	18.0	19.8
ASP1060 OD2 – LYS1086 NZ	12.1	0.3	0.0
ASP1060 OD1 – LYS1086 NZ	11.8	0.5	0.0
GLU1066 OE1 – ARG1069 NH2	10.1	18.6	33.3
GLU1066 OE2 – ARG1069 NH2	9.6	17.5	34.2
GLU1066 OE1 – ARG1069 NH1	9.0	22.1	37.3
GLU1066 OE2 – ARG1069 NH1	8.6	21.5	37.9
GLU1040 OE1 – ARG1046 NH1	0.0	19.1	3.6
GLU1040 OE2 – ARG1046 NH1	0.0	18.0	3.5
GLU1040 OE2 – ARG1046 NH2	0.0	17.6	3.7
ASP1068 OD2 – ARG1069 NH2	0.1	12.7	1.6
ASP1068 OD1 – ARG1069 NH2	0.1	12.6	3.0
ASP1068 OD2 – ARG1069 NH1	0.2	10.2	0.8
ASP1068 OD1 – ARG1069 NH1	0.1	10.0	2.0
GLU1045 OE1 – ARG1046 NH2	3.7	5.7	15.1
GLU1045 OE2 – ARG1046 NH2	4.2	5.1	14.6
GLU1045 OE1 – ARG1046 NH1	2.3	3.6	12.6
GLU1045 OE2 – ARG1046 NH1	2.6	3.0	11.9

Supplementary Table 15: Binding parameters obtained upon fitting the SPR binding of AD1-ACTR variants to NCBD using a 1:1 association model with BiaEvaluation 3.2 software.

Temper-ature	AD1-ACTR variant	k_{on} (M^{-1}·s^{-1})	k_{off} (s^{-1})	K$_D$ (nM, from kinetics)	Chi² from kinetics (RU²)
20°C (293 K)	WT	1.20×10^6	0.286	238	0.25
	[1076mL]	1.28×10^6	0.339	264	0.17
	[1055mL]	1.46×10^6	0.031	21.6	1.0
	[1055mL;1076mL]	2.71×10^6	0.021	7.57	1.1
22°C (295 K)	WT	1.21×10^6	0.356	295	0.20
	[1076mL]	1.35×10^6	0.410	304	0.14
	[1055mL]	1.54×10^6	0.036	23.4	0.88
	[1055mL;1076mL]	2.97×10^6	0.024	8.06	0.96
25°C (298 K)	WT	1.09×10^6	0.406	374	0.17
	[1076mL]	1.07×10^6	0.521	489	0.07
	[1055mL]	1.85×10^6	0.049	26.3	1.2
	[1055mL;1076mL]	3.77×10^6	0.030	7.84	0.69
27°C (300 K)	WT	1.02×10^6	0.454	448	0.19
	[1076mL]	1.07×10^6	0.526	493	0.15
	[1055mL]	1.78×10^6	0.059	33.3	1.2
	[1055mL;1076mL]	3.20×10^6	0.034	10.6	0.76
31°C (304 K)	WT	7.14×10^5	0.602	843	0.15
	[1076mL]	7.72×10^5	0.696	902	0.10
	[1055mL]	1.57×10^6	0.084	53.3	0.53
	[1055mL;1076mL]	3.03×10^6	0.055	18.1	0.60

Supplementary Table 16: Steady-state analysis of SPR data with a 1:1 binding isotherm model.

Temperature	AD1-ACTR variant	K_D (nM ± uncertainty)	R_{max} (RU ± uncertainty)
20 °C (293 K)	WT	180 ± 24	1.018 ± 0.041
	[1076meLeu]	199 ± 35	0.768 ± 0.041
	[1055meLeu]	31.6 ± 0.2	1.147 ± 0.001
	[1055meLeu;1076meLeu]	15.3 ± 0.2	1.543 ± 0.002
22 °C (295 K)	WT	186 ± 25	1.007 ± 0.041
	[1076meLeu]	208 ± 39	0.714 ± 0.041
	[1055meLeu]	33.2 ± 0.1	1.134 ± 0.001
	[1055meLeu;1076meLeu]	15.9 ± 0.2	1.375 ± 0.002
25 °C (298 K)	WT	233 ± 38	0.973 ± 0.051
	[1076meLeu]	268 ± 57	0.635 ± 0.046
	[1055meLeu]	35.5 ± 0.3	1.070 ± 0.002
	[1055meLeu;1076meLeu]	16.7 ± 0.2	1.114 ± 0.002
27 °C (300 K)	WT	251 ± 36	1.090 ± 0.053
	[1076meLeu]	270 ± 51	0.704 ± 0.046
	[1055meLeu]	43.8 ± 0.3	1.320 ± 0.002
	[1055meLeu;1076meLeu]	22.1 ± 0.4	1.287 ± 0.003
31 °C (304 K)	WT	388 ± 63	1.203 ± 0.077
	[1076meLeu]	396 ± 90	0.700 ± 0.064
	[1055meLeu]	69.2 ± 0.1	1.526 ± 0.001
	[1055meLeu;1076meLeu]	30.2 ± 0.2	1.177 ± 0.001

Supplementary References

1. Schmidtgall, B., Chaloin, O., Bauer, V., Sumyk, M., Birck, C., Torbeev, V. Dissecting mechanism of coupled folding and binding of an intrinsically disordered protein by chemical synthesis of conformationally constrained analogues. *Chem. Commun.* **53**, 7369-7372 (2017).

2. Stavropoulos, G., Gatos, D., Magafa, V., Barlos, K. Preparation of polymer-bound trityl-hydrazines and their application in the solid phase synthesis of partially protected peptide hydrazides. *Lett. Pept. Sci.* **2**, 315-318 (1995).

3. Zheng, J.-S., Tang, S., Guo, Y., Chang, H. N., Liu, L. Synthesis of cyclic peptides and cyclic proteins via ligation of peptide hydrazides. *ChemBioChem* **13**, 542-546 (2012).

4. Fang, G.-M., Wang, J. X., Liu, L. Convergent chemical synthesis of proteins by ligation of peptide hydrazides, *Angew. Chem. Int. Ed.* **51**, 10347-10350 (2012).

5. Bekesi, A., Abdellaoui, S., Holroyd, N., Van Delm, W., Pardon, E., Pauwels, J., Gevaert, K., Steyaer, J., Derveaux, S., Borysik, A., Tompa, P. Challenges in the structural–functional characterization of multidomain, partially disordered proteins CBP and p300: preparing native proteins and developing nanobody tools. *Methods Enzymol.* **611**, 607-675 (2018).

6. Keller, S., Vargas, C., Zhao, H., Piszczek, G., Brautigam, C. A., Schuck, P. High-precision isothermal titration calorimetry with automated peak-shape analysis. *Anal. Chem.* **84**, 5066-5073 (2012).

7. Scheuermann, T. H., Brautigam, C. A. High-precision, automated integration of multiple isothermal titration calorimetric thermograms: New features of NITPIC. *Methods* **76**, 87-98 (2015).

8. Brautigam C. A., Zhao, H., Vargas, C., Keller, S., Schuck, P. Integration and global analysis of isothermal titration calorimetry data for studying macromolecular interactions, *Nat. Protocols* **11**, 882-894 (2016).

9. Iešmantavičius, V., Dogan, J., Jemth, P., Teilum, K., Kjaergaard, M. Helical propensity in an intrinsically disordered protein accelerates ligand binding. *Angew. Chem. Int. Ed.* **53**, 1548-1551 (2014).

10. Kwok, S. C., Hodges, R. S. Stabilizing and destabilizing clusters in the hydrophobic core of long two-stranded alpha-helical coiled-coils. *J. Biol. Chem.* **279**, 21576-21588 (2004).

11. Wishart, D. S., Bigam, C. G., Yao, J., Abildgaard, F., Dyson, H. J., Oldfield, E., Markley, J. L., Sykes, B. D. ^{1}H, ^{13}C and ^{15}N chemical shift referencing in biomolecular NMR. *J. Biomol. NMR* **6**, 135-140 (1995).

12. Kay, L. E., Torchia, D. A., Bax, A. Backbone dynamics of proteins as studied by N-15 inverse detected heteronuclear NMR-spectroscopy - application to staphylococcal nuclease. *Biochemistry* **28**, 8972-8979 (1989).

13. Vranken, W. F., Boucher, W., Stevens, T. J., Fogh, R. H., Pajon, A., Llinas, M., Ulrich, E. L., Markley, J. L., Ionides, J., Laue, E. D. The CCPN Data Model for NMR Spectroscopy: Development of a Software Pipeline. *Proteins* **59**, 687-696 (2005).

14. Nielsen, J. T., Mulder, F. A. A. POTENCI: prediction of temperature, neighbor and pH-corrected chemical shifts for intrinsically disordered proteins. *J. Biomol. NMR* **70**, 141-165 (2018).

15. Kabsch, W. XDS. *Acta Crystallogr. D (Biol. Crystallogr.)* **66**, 125-132 (2010).

16. Jin, T., Chuenchor, W., Jiang, J., Cheng, J., Li, Y., Fang, K., Huang, M., Smith, P., Xiao T. S. Design of an expression system to enhance MBP-mediated crystallization. *Sci. Rep.* **7**, 40991 (2017).

17. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., Read, R. J. Phaser crystallographic software. *J. Appl. Crystallogr.* **40**, 658-674 (2007).

18. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D (Biol. Crystallogr.)* **66**, 213-221 (2010).

19. Moriarty, N. W., Grosse-Kunstleve, R. W., Adams, P. D. electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation. *Acta Crystallogr. D (Biol. Crystallogr.)* **65**, 1074-1080 (2009).

20. Painter, J., Merritt, E. A. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. *Acta Crystallogr. D (Biol. Crystallogr.)* **62**, 439-450 (2006).

21. Schmid, N., Christ, C. D., Christen, M., Eichenberger, A. P., van Gunsteren, W. F. Architecture, implementation and parallelisation of the GROMOS software for biomolecular simulation. *Comput. Phys. Commun.* **183**, 890-903 (2012).

22. www.gromos.net (accessed July 20, 2019).

23. Poger, D., van Gunsteren, W. F., Mark, A. E. A new force field for simulating phosphatidylcholine bilayers. *J. Comput. Chem.* **31**, 1117-1125 (2010).

24. Schmid, N., Eichenberger, A. P., Choutko, A., Riniker, S., Winger, M., Mark, A. E., van Gunsteren, W. F. Definition and testing of the GROMOS force-field versions 54A7 and 54B7. *Eur. Biophys. J.* **40**, 843-856 (2011).

25. Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., Hermans, J. Interaction models for water in relation to protein hydration. In *Intermolecular Forces*; Pullman, B., Ed.; Reidel: Dordrecht, The Netherlands, 1981; pp 331-342.

26. Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., DiNola, A., Haak, J. R. Molecular dynamics with coupling to an external bath. *J. Chem. Phys.* **81**, 3684-3690 (1984).

27. Ryckaert, J. P., Ciccotti, G., Berendsen, H. J. C. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. *J. Comput. Phys.* **23**, 327-341 (1977).

28. Tironi, I. G., Sperb, R., Smith, P. E., van Gunsteren, W. F. A generalized reaction field method for molecular dynamics simulations. *J. Chem. Phys.* **102**, 5451-5459 (1995).

29. Glättli, A., Daura, X., van Gunsteren, W. F. Derivation of an improved simple point charge model for liquid water: SPC/A and SPC/L. *J. Chem. Phys.* **116**, 9811-9828 (2002).

30. Eichenberger, A. P., Allison, J. R., Dolenc, J., Geerke, D. P., Horta, B. A. C., Meier, K., Oostenbrink, C., Schmid, N., Steiner, D., Wang, D. Q., van Gunsteren, W. F. GROMOS++ software for the analysis of biomolecular simulation trajectories. *J. Chem. Theory Comput.* **7**, 3379-3390 (2011).

31. Daura, X., van Gunsteren, W. F., Mark, A. E. Folding-unfolding thermodynamics of a β-heptapeptide from equilibrium simulations. *Proteins* **34**, 269-280 (1999).

32. Fournane, S., Charbonnier, S., Chapelle, A., Kieffer B., Orfanoudakis, G., Travé, G., Masson, M., Nominé, Y. Surface plasmon resonance analysis of the binding of high-risk mucosal HPV E6 oncoproteins to the PDZ1 domain of the tight junction protein MAGI-1. *J. Mol. Recognit.* **24**, 511 (2010).